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CHAPTER I 
 
INTRODUCTION 
 
Overview of Thesis 
 Cell migration is a highly integrated multistep process that is vital for embryonic 
development, the inflammatory response, tissue repair and regeneration, maintaining 
homeostasis in the adult, and many other important cellular processes (Lauffenburger and 
Horwitz, 1996). Aberrant cell migration, on the other hand, contributes to many pathological 
disorders such as atherosclerosis, arthritis, and tumor cell metastasis. Indeed, an essential first 
step in forming deadly metastases is the migration of cancer cells away from the primary tumor 
into the surrounding tissue. Because of the many functions that cell migration serves, it is 
important to understand how cells migrate, which molecules are involved, and how their 
interactions elicit biological responses. 
 The process of cell movement is highly coordinated and is dependent on proper 
regulation of the actin cytoskeleton. Therefore, reorganization of actin must be tightly controlled. 
Such remodeling of the actin cytoskeleton is regulated by proteins of the Rho family of GTPases, 
including Rac and Rho. Once activated, these GTPases then interact with downstream effector 
proteins to modulate actin and thereby regulate cell migration. Various Rho GTPases have been 
shown to be upregulated in human tumors, including breast and prostate cancer. Therefore, 
identifying and characterizing regulators of Rho GTPases, such as the guanine nucleotide 
exchange factors (GEFs), and determining their role in cancer cells is greatly needed.  
 Asef2 is a recently identified GEF known to activate both Rac and Cdc42, but its role in 
regulating cancer cell migration is not well understood. Data from this thesis suggest a novel role 
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for Rac in regulating actomyosin contractility and cell migration (Jean et al., 2013).  Activation 
of Rac by Asef2 inhibits cell migration by increasing Myosin II-dependent cell contractility, 
which has classically been thought to be mediated by Rho (Chrzanowska-Wodnicka and 
Burridge, 1996; Wheeler and Ridley, 2004). Using high-end optical imaging techniques, this 
thesis investigates the mechanisms by which Rac signaling regulates Myosin II-dependent 
contractility and the force-generating mechanical signals that modulate cell migration. Since 
little is known about Rac-mediated force generation through Myosin II, this body of work 
provides novel insight into how the Rac-Myosin II pathway regulates cell migration and its 
underlying processes. 
 
The Extracellular Matrix 
 Cells migrate on an extracellular matrix (ECM), which is essentially the non-cellular 
component present within all tissues and organs that provide essential physical scaffolding for 
the cellular constituents and also critical biochemical and biomechanical cues to direct cell 
growth, survival and migration among others (Frantz et al., 2010). The ECM can exist either as 
complex three-dimensional (3D) networks of macromolecules in which cells are embedded, or as 
basement membranes laid down by cells to form a structural framework for tissue organization 
(Frantz et al., 2010; Hynes, 2009; Lawson and Burridge, 2014).  
 The ECM is comprised of an interweaving mesh of fibrous proteins such as collagen and 
fibronectin, and various proteoglycans (Fig. 1) (Frantz et al., 2010). Collagen is the most 
abundant fibrous protein within the ECM architecture and constitutes up to 30% of the total 
protein mass of a multicellular organism (Frantz et al., 2010).  Collagen is predominantly 
transcribed and secreted by fibroblasts that either reside in the stroma or are recruited to it from 
neighboring tissues (De Wever et al., 2008).  By exerting tension on the matrix, fibroblasts are  
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Figure 1. Schematic of the extracellular matrix. The ECM is composed of three major classes 
of molecules: 1) structural proteins, such as collagen, 2) specialized proteins, such as: fibronectin 
and 3) proteoglycans, which are complex proteins that are covalently bonded at multiple sites 
along the protein chain to a class of polysaccharides, known as glycosaminoglycans. 
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able to organize collagen fibrils into sheets and cables and, thus, can dramatically influence the 
alignment of collagen fibers within tissues (Frantz et al., 2010). As the main structural element of 
the ECM, collagen provides tensile strength, regulate cell adhesion and direct tissue development 
(Rozario and DeSimone, 2010). Fibronectin, which is produced by a wide variety of epithelial 
and mesenchymal cells, also play a crucial role in cell adhesion, migration, growth and 
differentiation. Fibronectin is also found in basement membranes and in loose connective tissue 
stroma. Active fibronectin fibrillogenesis (i.e. development of fine fibrils) by cells is usually 
required for Collagen I matrix assembly in vivo.  
ECM proteins typically include multiple independently folded domains whose sequences 
and arrangement are highly conserved. Some of these domains bind adhesion receptors, such as 
integrins to mediate cell-matrix adhesion and also transduce signals into cells (Hynes, 2009). 
Because of its diverse nature and composition, the ECM can have many functions, such as 
providing support, segregating tissues, and regulating intercellular communication.  
The actin cytoskeleton 
Cell migration consists of several critical steps that are highly dependent on the 
continuous reorganization and turnover of the actin cytoskeleton (Ridley, 2011). The actin 
cytoskeleton, which consists of arrays of functionally different subsets of intracellular actin 
filament,	  provides the structural framework that define cell shape and polarity. At the front or 
leading edge of migrating cells, actin is organized into several distinct structures and its 
polymerization in these cellular protrusions drives cell migration. Protrusions generally contain 
two actin-based structures (Fig. 2), the lamellipodium and the lamellum, with the lamellipodium 
spatially anterior to the lamellum (Heath and Holifield, 1991; Vicente-Manzanares et al., 2009b).  
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Figure 2. Schematic of the actin cytoskeleton of a migrating fibroblast. At the cell front, the 
lamellipodium contain polarized branched F-actin networks that drive membrane extension. The 
flat region behind the lamellipodium and in front of the nucleus (N) is termed the lamella. The 
cell attaches to the substrate at adhesion sites. At the center of the cell, actin filaments form bipo-
lar assemblies with myosin to form contractile arrays (for retracting).  
 
Figure taken from the web page of the Vic Small lab of the Austrian Academy of Sciences in 
Salzburg and Vienna. http://cellix.imba.oeaw.ac.at/cytoskeleton/actin 
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The lamellipodium is rich in cross-linked dendritic F-actin arrays facilitated primarily by the 
actin nucleator Arp2/3 and cofilin (Pollard and Borisy, 2003; Small, 1988).  Extending from the 
lamellipodium are thinner protrusions called filopodia, which are composed of thin bundled actin 
filaments that actively search the environment and promote directional cell migration (Mattila 
and Lappalainen, 2008). The actin filament network of the lamellum consist primarily of 
condensed linear actin bundles, and thus is more stable and less dynamic than that of 
lamellipodia (Ponti et al., 2004). Furthermore, the lamellipodium and the lamellum are 
kinetically different. Whereas the lamellipodium is characterized by a fast retrograde flow of 
actin, the lamellum exhibits slower retrograde flow (Ponti et al., 2004). The convergent zone 
between the two is characterized by active depolymerization of the branched dendritic network 
and the reorganization of actin (Vicente-Manzanares et al., 2009b).  Essentially, the dynamic 
properties of actin filaments provide the driving force for cells to move by giving them the 
ability to 1) push via polymerization and 2) contract via interaction with motor proteins.  
 
The Migration Cycle  
 Migration may be viewed as a repetitive, multistep cycle (Fig. 3) which includes 
extension of a protrusion, usually induced by an exogenous agent, formation of stable 
attachments (adhesions) near the leading edge of the protrusion, translocation of the cell body 
forward, and release of adhesions along with retraction at the cell rear (Lauffenburger and 
Horwitz, 1996; Lee et al., 1993; Sheetz, 1994).  Polymerization of the actin cytoskeletal network 
is thought to drive the initial extension of the membrane protrusion at the cell front, termed 
lamellipodia (Borisy and Svitkina, 2000; Carson et al., 1986; Wang, 1985). The interaction of the 
integrin family of transmembrane receptors with the ECM initiates the formation of adhesions by 
recruiting signaling and structural proteins, such as paxillin and vinculin, to these sites (Burridge 
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and Chrzanowska-Wodnicka, 1996; Miyamoto et al., 1995a; Miyamoto et al., 1995b; 
Schoenwaelder and Burridge, 1999; Yamada and Miyamoto, 1995; Zaidel-Bar et al., 2003). In 
turn, these small nascent adhesions stabilize the protrusion and transmit strong forces, which 
serve as traction points for the forces that move the cell body forward (Beningo et al., 2001; 
Galbraith and Sheetz, 1997; Lee et al., 1994).  These nascent adhesions can continue to grow and 
mature into large focal adhesions. Alternatively, after assembly, the adhesions at the leading 
edge of the cell must disassemble for migration to continue (Laukaitis et al., 2001; Webb et al., 
2004). The process of adhesion assembly and disassembly at the leading edge is termed adhesion 
turnover (Webb et al., 2002). 
 Cell body translocation is independent of actin polymerization (Anderson et al., 1996). 
Myosin II motor proteins, which bind and slide anti-parallel actin filaments that are anchored to 
adhesions, generate traction force on the substratum and provide the contractile force needed for 
translocation (Parsons et al., 2010; Svitkina et al., 1997). The actomyosin cytoskeleton also 
promotes adhesion disassembly and retraction of the rear of migrating cells to allow the cell to 
move forward (Chrzanowska-Wodnicka and Burridge, 1996; Crowley and Horwitz, 1995; 
Worthylake et al., 2001). Release of adhesions and retraction at the rear completes the migratory 
cycle (Lauffenburger and Horwitz, 1996; Lee et al., 1993; Sheetz, 1994).  While some progress 
has been made over the last few years, many of the signaling pathways that regulate these 
processes still remain to be identified.   
 It is crucial that each step of the migration process be tightly controlled for proper 
function. For instance, a cell’s failure to rapidly disassemble its adhesions prevents its 
disengagement from the ECM, and thus delay or disrupt its migration process.  All of these 
migratory steps form a cyclic process that is dependent on the coordination of cell adhesion to  
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Figure 3. The migration cycle. 1) Polymerization of actin filaments at the leading edge is 
translated into a protrusive force to initiate cell migration. This begins with the extension of an 
actin-rich protrusion. 2) Membrane protrusion facilitates the binding of transmembrane cell 
surface receptors to the substratum components. New adhesions are rapidly linked to the network 
of actin filaments. This protrusion is then stabilized by the formation of cell-matrix adhesions. 3) 
The combined activity of retrograde actin flow and contraction forces generates tensions that 
allow the cell body to translocate in the direction of the migration. 4) The forces produced by the 
contractile network combined with actin filament and FA disassembly help to retract the trailing 
cell edge.  
Used by permission from MBInfo: www.mechanobio.info; Mechanobiology Institute, National 
University of Singapore. 
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the ECM and the cell’s ability to contract its body in order to move in a sustained migration (Fig. 
2). Since adhesion dynamics and cell contractility play such an important role in regulating cell 
migration, these two aspects of migration will be the main focus of this dissertation. 
Cell Adhesion - Composition 
 The adhesion of cells to the ECM is mainly mediated by heterodimeric transmembrane 
receptors, named integrins that are composed of one α-chain in non-covalent association with 
one β-chain. Both subunits typically have large extracellular but short intracellular domains. The 
extracellular domains of integrins bind directly to specific sequence motifs within ECM proteins, 
such as collagen, while the short intracellular tail domains interact directly or indirectly with 
various intracellular adhesion proteins (Hynes, 2002). The binding of integrins to their ECM 
ligands induces a conformational change that unmasks their short cytoplasmic tails. The exposed 
cytoplasmic tail promote the recruitment and formation of multiprotein complexes that connects 
the integrins-ECM complex to the actin cytoskeleton (Hynes, 2002; Vicente-Manzanares et al., 
2009a). For instance, ligand binding induces the recruitment of scaffold and signaling proteins 
such as paxillin and the protein Tyr kinase focal adhesion kinase (FAK), respectively (Parsons, 
2003). In turn, these proteins associate with additional molecules that regulate signaling to Rho 
GTPases, which are regulatory proteins that serve as a convergence point between actin re-
organization and adhesion dynamics (Brown and Turner, 2004; Parsons et al., 2010). 
 In addition to their role in biochemical signaling pathways, integrins are also 
mechanotransducers in that they convert a mechanical stimulus into a biochemical signal.  Cells 
use their integrins to detect the varying changes in their environment and the architecture of the 
ECM (i.e. such as ECM stiffness). The cell’s response to these changes can vary from 
strengthening the associated adhesions, re-organizing the cytoskeleton and remodeling the ECM 
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(Roca-Cusachs et al., 2012; Schwartz and DeSimone, 2008). Integrin α5β1 is a major cellular 
receptor for the ECM protein fibronectin and plays a fundamental role during mammalian 
development. Binding of α5β1 integrin to Fn molecules results in integrin clustering and 
stimulates an intracellular signaling cascade which recruits adhesion proteins to the actin 
cytoskeleton (To and Midwood, 2011). 
 Integrin-based adhesions are highly complex structures and are composed of over 150 
different protein-protein interactions (Geiger et al., 2009; Geiger and Yamada, 2011; 
Huttenlocher and Horwitz, 2011).  As such, they appear in a variety of sizes, morphologies, and 
locations depending on the cell and its environment.  Although a robust categorization of 
adhesions has not been described, definite subclasses have now been identified, e.g., nascent 
adhesions, focal complexes (FCs), focal adhesions (FAs), and fibrillar adhesions (Geiger and 
Yamada, 2011; Vicente-Manzanares et al., 2009b; Zaidel-Bar et al., 2004).  Fibrillar adhesions, 
which are characterized by long lifetimes and a highly elongated structure, are specialized 
adhesions involved in ECM modification (Broussard et al., 2008; Brown and Turner, 2004; 
Parsons et al., 2010; Rid et al., 2005; Zamir et al., 2000).  Fibrillar adhesions are not the focus of 
this dissertation since previous studies demonstrated that they are not typically present in rapidly 
migrating cells (Huttenlocher and Horwitz, 2011). 
 Nascent adhesions and focal complexes are small, dynamic, and dot-like adhesions that 
are found near the leading edge in protrusions and they have been shown to mediate signals that 
promote actin polymerization (Alexandrova et al., 2008) (Choi et al., 2008). Nascent adhesions 
form concurrently with lamellipodial protrusion and are less than the 0.25 µm resolution of most 
light microscopy techniques (Choi et al., 2008). Some of these nascent adhesions will further 
mature into FCs (0.5 µm)- adhesion contacts found at the tip of extending protrusions, and then 
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to FAs (1-5 µm) (Choi et al., 2008), which are more stable, and more highly organized at the rear 
and sides of the cell (Zaidel-Bar et al., 2003).  Focal adhesions, which are the best characterized 
of the cell-matrix adhesions, are the resulting transmembrane junctions between the ECM and 
the cell cytoskeleton (Burridge et al., 1988). Interestingly, an inverse correlation between the size 
and organization of focal adhesions and cell migration speed has been observed (Lauffenburger 
and Horwitz, 1996). Indeed, migration rates have been shown to be highly sensitive to adhesive 
strength (Palecek et al., 1997).  Whereas an optimal adhesive environment supports maximal 
migration, too weak or too strong adhesive environments prevent formation of new adhesions or 
retraction of trailing adhesions, respectively. Therefore, this suggests that the rates of cell 
migration are not fixed, but rather are modulated by physical cues in the extracellular 
environment. 
 The proteins in FAs (Fig. 4) vary widely in function as they can either link integrins to 
the actin cytoskeleton and/or recruit other molecules to adhesions. The best studied scaffolding 
and signaling proteins in FAs are paxillin, talin, vinculin and zyxin.  Whereas talin transitions 
integrins to an active state by linking their cytoplasmic tail to actin and to vinculin (Campbell 
and Ginsberg, 2004), vinculin directly binds F-actin and the actin cross-linking protein, α-actinin 
(Otey and Carpen, 2004; Ziegler et al., 2006). Several protein kinases have also been shown to 
be part of the plethora of signaling molecules that associate with integrin-containing adhesions. 
Kinases, such as FAK, Abelson kinase (Abl) and Src kinase, regulate adhesion signaling by 
phosphorylating many early adhesion proteins, such as paxillin and Cas, to recruit additional 
molecules (Parsons, 2003). Paxillin and Cas bind the additional regulatory proteins that control  
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Figure 4. Schematic of focal adhesion nanoscale architecture and composition. The 
extracellular domains of integrins bind the ECM, while their cytoplasmic tails interact with the 
integrin signaling layer, such as FAK and paxillin. The force transduction layer contains the 
tension sensitive proteins such as talin and vinculin. Finally, the actin regulatory layer, which 
includes zyxin, VASP and α-actinin, link the adhesion to an actin stress fiber (contractile 
machinery).  
 
Reprinted from (Kanchanawong, Shtengel et al. 2010)  
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the activity of the Rho GTPases, which then modulate actin remodeling and adhesion dynamics 
(Defilippi et al., 2006; Mitra and Schlaepfer, 2006; Peacock et al., 2007; Tomar and Schlaepfer, 
2009). 
Cell Adhesion - Turnover 
 Polarized cell migration requires continuous assembly and disassembly of cell-matrix 
adhesions (Fig. 5) and the constant remodeling of the associated actin cytoskeleton.  The 
constant assembly and disassembly of leading edge adhesions, termed adhesion turnover, is 
crucial for efficient cell migration (Webb et al., 2002). 
 The earliest detectable adhesions, or nascent adhesions, form in the lamellipodium just 
behind the leading edge. These adhesions contain integrins, talin, vinculin, α-actinin, paxillin and 
FAK, among other proteins, and are enriched in phosphotyrosine (Choi et al., 2008). Protein 
phosphorylation, which is carried out by kinases, is the most common mechanism of regulating 
protein function and transmitting signals throughout the cell. Therefore, an enrichment of 
phosphotyrosine residues is indicative that these adhesions are active signaling complexes.   
 Once formed, nascent adhesions at the leading edge exert traction forces on the ECM 
(Beningo et al., 2001). High traction forces are typically observed at the cell front. As the leading 
edge of a migrating cell moves forward, nascent adhesions can either mature into larger 
stabilized adhesions; or they can undergo rapid turnover such that their components can be 
incorporated into newly formed adhesion sites (Bershadsky et al., 2003). Paxillin-containing 
adhesions near the leading edge have been shown to be highly dynamic, and to rapidly form and 
turn over (Choi et al., 2008; Webb et al., 2004). The formation and life cycle of nascent 
adhesions appear to be intimately linked to actin polymerization and organization (Alexandrova 
et al., 2008; Choi et al., 2008). Whereas actin polymerizes rapidly near the front of the 
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Figure 5. Model of adhesion dynamics. Nascent adhesions formed at the front either undergo 
turnover, which is predominantly controlled by kinase signaling, or mature in response to 
contractile forces. Mature adhesions can either disassemble or be transformed into fibrillar 
adhesions. Trailing adhesions arise as a result of fusion of additional nascent adhesions and 
remaining fibrillar adhesions. Once formed, trailing adhesions slide because of tension from 
attached stress fibers and either eventually disassemble or detach and leave integrin trails behind.  
 
Reprinted from (Broussard, Webb et al. 2008) 
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lamellipodium as a branched array of filaments, it depolymerizes at locations more distal to the 
leading edge and tends to be more bundled (Pollard and Borisy, 2003). Therefore, as nascent 
adhesions approached the end of the lamellipodium, which is an area of actin disassembly, they 
either disassemble or begin to elongate and grow (i.e. mature).  Inhibitors of actin polymerization 
have been shown to impair the formation of nascent adhesions (Alexandrova et al., 2008; Choi et 
al., 2008).  Essentially, while branched actin in the lamellipodium provides a physical scaffold 
for nascent adhesions, actin depolymerization by cofilin can decouple these nascent adhesions 
from actin that then leads to adhesion disassembly (Oser and Condeelis, 2009). 
 While the majority of nascent adhesions undergo rapid turnover, a few undergo 
maturation behind the leading edge in response to tensile stress (Bershadsky et al., 2003). 
Nascent adhesions grow larger at the border of the lamellipodium and lamellum, and they show a 
differential increase in certain adhesion components like vinculin and α-actinin as they become 
focal complexes (FCs).  This occurs when the protrusion experiences periodic or occasional 
pauses in forward movement in response to myosin II-dependent contractile events (Alexandrova 
et al., 2008; Choi et al., 2008; Vicente-Manzanares et al., 2008). The actin cross-linking protein, 
α-actinin, is suggested to play a crucial role in adhesion maturation.  As one of the initial 
components detected in maturing adhesions, it has been shown to accumulate with actin 
filaments before other adhesion components (Choi et al., 2008; Parsons et al., 2010).   
 Adhesions mature along thin actin bundles that originate near the transition zone at the 
lamellipodium-lamellum interface. FCs, located at the lamellipodium-lamellum interface, 
represent an initial step in the maturation process (Ridley and Hall, 1992a; Rottner et al., 1999).  
Although their molecular constituents are similar to those found in nascent adhesions, they are 
highly dependent on myosin II activity (Choi et al., 2008; Ridley and Hall, 1992a; Rottner et al., 
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1999).  They are also a transient entity and thus as the lamellipodium moves forward, they 
mature into larger, elongated focal adhesions (FAs) (Choi et al., 2008). The addition of 
components during this elongation and growth process is sequential.  Paxillin, for example, 
enters early, whereas vinculin enters later. Studies using GFP-tagged proteins have shown that 
paxillin and α-actinin join the adhesion sequentially (Webb et al., 2002).  The maturation process 
of FAs can continue to occur over a long period of time, as the adhesions remain fixed when the 
forward movement of the protrusion (and cell) moves over them. As traction forces move the cell 
forward, FAs that are underneath the incoming cell body either disassemble or become fibrillar 
adhesions, which essentially represent the endpoint in terms of adhesion maturation (Broussard 
et al., 2008; Brown and Turner, 2004; Parsons et al., 2010). Maturation of focal adhesions is 
mediated by increased tension force and local actin polymerization (Bershadsky et al., 2006; 
Geiger et al., 2001).   
 FAs are elongated in morphology and reside at the ends of large actin bundles or stress 
fibers (Zimerman et al., 2004) that extend from near the front of the cell along the peripheral 
sides to the cell center or the rear. Being larger and more stable, FAs are composed of a 
heterogeneous class of adhesions with a spectrum of sizes that reflects the continuous process of 
adhesion maturation (Geiger and Yamada, 2011; Kanchanawong et al., 2010; Vicente-
Manzanares et al., 2011). By contrast with FCs, FAs are enriched in the associated proteins 
including paxillin, talin, α-actinin and vinculin. The mechanisms that regulate the decision to 
disassemble or to elongate and grow are not well understood.  However, the general notion is 
that myosin II-dependent contraction puts tension on adhesion molecules and induces changes in 
their conformation, thus opening new sites for binding or post-translational modification 
(Sawada et al., 2006). 
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 Protein phosphorylation plays important roles in regulation of FAs formation and 
turnover (Webb et al., 2004).  In protrusions, FAK and Src tyrosine kinases are the regulators of 
adhesion turnover. For instance, fibroblasts or cancer cells from FAK null mice have an 
increased number of large peripheral adhesions with impaired turnover leading to slower 
migration (Ilic et al., 1995).  Fibroblasts from mice either lacking Src kinases or ectopically 
expressing kinase-dead c-Src also show large peripheral adhesions with reduced turnover, and 
impaired migration (Fincham and Frame, 1998; Klinghoffer et al., 1999; Webb et al., 2004).  But 
in contrast, FA disassembly was induced when these cells were infected with the Rous sarcoma 
virus, which promotes activation of Src.  FAK has also been shown to be required for adhesion 
disassembly (Tilghman et al., 2005).  The scaffold functions of FAK seem to be important in the 
recruitment of regulators of Rho GTPases, which can mediate local myosin contractility and 
thereby adhesion maturation and disassembly (Tomar and Schlaepfer, 2009; Webb et al., 2004). 
These studies indicate an essential role for FAK/Src signaling in adhesion turnover. 
 Besides phosphorylation-dependent regulation, several other mechanisms can also 
contribute to the turnover process (Fig. 5).  These mechanisms include microtubule targeting 
(Kaverina et al., 1999), proteolysis of adhesion proteins (Chan et al., 2010; Cortesio et al., 2011; 
Franco et al., 2004), and non-muscle myosin II-based cell contraction (Chrzanowska-Wodnicka 
and Burridge, 1996). Mature adhesions in the central region of the cell undergo microtubule and 
FAK-mediated mechanism of disassembly (Ezratty et al., 2005). This microtubule-induced 
disassembly is characterized by integrin endocytosis at adhesion sites regulated by clathrin and 
specific clathrin adaptor proteins (Ezratty et al., 2009).  Microtubule-mediated turnover of FAs is 
thought to be through the modulation of Rho GTPase signaling (Broussard et al., 2008). 
 The Ca
2+
-activated protease calpain also mediates adhesion disassembly in retracting 
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regions (Franco and Huttenlocher, 2005).  Calpain cleavage of several proteins found in FAs, 
including FAK, paxillin and talin mediate adhesion disassembly and destabilize focal adhesions 
downstream from microtubules (Bhatt et al., 2002). Specifically, calpain-mediated proteolysis 
has been shown to stimulate the dissociation of major adhesion components such as paxillin, 
vinculin and zyxin (Franco et al., 2004). Calpain inhibition by chemical inhibitors, biological 
agents (such as calpastatin) and genetic deletion block disassembly (Franco and Huttenlocher, 
2005).  Calpain-based mechanisms appear to be particularly important for disassembly of 
adhesions that are found at the rear of the cell (Huttenlocher et al., 1997). 
 In addition to regulating adhesion turnover at the leading edge, FAK, Src, and other 
regulators of phosphorylation likely play a key role in adhesion disassembly at the rear 
(Huttenlocher and Horwitz, 2011).  For example, adhesion disassembly can occur through FAK-
Src signaling via regulation of myosin-light chain kinase (MLCK) and ERK (Webb et al., 2004). 
Myosin II activity, and thereby cell contractility, is involved in FA disassembly at the trailing 
edge.  Furthermore, fibroblasts deficient in myosin IIA show impaired adhesion disassembly and 
rear detachment (Vicente-Manzanares et al., 2007). Lastly, FAK may regulate adhesion 
disassembly through its association with calpain and ERK at focal adhesions (Carragher et al., 
2003). 
 For adhesion disassembly during retraction of the trailing edge, the adhesions at the rear 
often move centripetally and then disassemble, leaving integrin trails on the substratum (Ezratty 
et al., 2005; Laukaitis et al., 2001; Regen and Horwitz, 1992). Although not fully understood, 
adhesion sliding seems to be a Rho GTPase- and myosin II-dependent form of treadmilling, 
during which components are released at the rear of the adhesion and enter new adhesions in the 
proximal region (Ballestrem et al., 2001; Digman et al., 2008). Thus, though the whole adhesion 
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moves, individual components exchange in and out of it but otherwise remain stationary. As a 
result, integrins, instead of the cytoplasmic components of adhesions, remain associated with the 
substratum while the cytoskeleton-associated components translocate toward the cell body and 
disperse as the adhesion disassembles (Regen and Horwitz, 1992; Smilenov et al., 1999).  This 
indicates a severing between integrin and the cytoplasmic components of the adhesion during 
release (Palecek et al., 1998).  Post-translational modifications such as change in 
phosphorylation or proteolysis can contribute to the severing of linkages at the cell’s rear. 
However, this effect is blocked by a myosin II inhibitor (Crowley and Horwitz, 1995), 
suggesting that it may also be tension-dependent. Thus, contractile forces at the cell’s rear are 
likely key regulators of adhesive release by weakening integrin-substrate or integrin-cytoskeletal 
interactions (Huttenlocher and Horwitz, 2011; Worthylake et al., 2001). 
 
Myosin II and migration 
 The interaction of myosin II motor proteins with actin filaments has recently emerged as 
a major force-generating apparatus in cell migration. Contraction of actin filaments is mediated 
by MyoII, which moves antiparallel actin filaments past each other and thereby provides the 
force that rearranges the actin cytoskeleton (Parsons et al., 2010). MyoII is also able to bundle 
actin filaments due to its oligomeric nature and actin-binding properties (Fig. 6). Actin filaments 
in the central and rear regions of migrating cells are often organized into thick bundles called 
stress fibers (Amano et al., 1997). 
 Myosin II is a bipolar actin motor composed of two heavy chains (MHCII), two 
regulatory light chains (RLCs) and two essential light chains (ELCs).  While the RLCs regulate 
NM II activity, the ELC pair stabilize the heavy chains and there is no evidence that they 
undergo reversible phosphorylation (Vicente-Manzanares et al., 2009b). Each MHCII contains 
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an N-terminal head domain, a neck region, and a C-terminal α-helical rod domain (Wang et al., 
2011).  The head domains, which contain the ATPase motor region, bind to actin and allow 
MyoII to move along actin filaments by coupling the hydrolysis of ATP to conformational 
changes. The rod domains can associate with other MyoII rod domains to form bipolar filaments. 
These bipolar filaments generate contraction by sliding actin filaments relative to one another, 
which is a major cellular function of MyoII.  
 There are three major variants of myosin II: muscle, smooth muscle and non-muscle. 
While muscle myosin II is responsible for the contraction of the sarcomeres, smooth muscle and 
non-muscle myosin II are implicated in force generation and actin crosslinking that regulates cell 
migration (Aguilar-Cuenca et al., 2014; Vicente-Manzanares et al., 2009b). In mammals, MyoII 
has three isoforms, MyoIIA, MyoIIB and MyoIIC that are specified by the difference in their 
heavy chains. These three isoforms also have distinct intracellular localization and functions 
(Vicente-Manzanares et al., 2009b).  The studies included in this dissertation focus on the non-
muscle form of MyoII.  
 The activity and function of MyoII is regulated by phosphorylation of threonine 18 (T18) 
and serine 19 (S19) within the regulatory chain (Adelstein and Conti, 1975; Scholey et al., 1980). 
Whereas phosphorylation of S19 activates the motor domain of MyoII and drives actomyosin 
contractility (Adelstein and Conti, 1975; Ikebe, 1989), subsequent phosphorylation of T18 has an 
additive effect that further augments the ATPase activity of the motor (Ikebe, 1989; Umemoto et 
al., 1989). Moreover, phosphorylation of MyoII RLCs increases myosin II’s assembly into 
bipolar myosin filaments, which bundle actin (Parsons et al., 2010). 
 These phosphorylation events are controlled by several protein kinases and phosphatases, 
many of which are regulated by Rho GTPases. The active ATPase allows MyoII to move along  
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Figure 6. Schematic of the actomyosin. The subunit and domain structure of non-muscle 
myosin II, forms a dimer through interactions between the α-helical coiled-coil rod domains. 
MyoII molecules assemble into bipolar filaments through interactions between their rod 
domains. These filaments then bind actin through their head domains. Once the ATPase is 
activated at the head, there is a conformational change that moves actin filaments in an anti-
parallel manner. Bipolar myosin filaments link actin filaments together in thick bundles that form 
cellular structures such as stress fibers. 
Reprinted from Parsons et al. 2010 
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actin filaments by coupling the hydrolysis of ATP to conformational change (Fig. 6). The sliding 
of actin filaments relative to each other by MyoII generates the contractile forces seen in cells. 
Major insights on the function of the ATPase domain in actin motility have resulted from the use 
of synthetic drugs, most notably blebbistatin. Blebbistatin, which was identified in a small 
molecule screening, was first reported to impair cytokinesis and cell migration (Straight et al., 
2003). The molecular mechanism behind blebbistatin activity revealed that it does not block the 
ATPase activity of MyoII, but instead slows down the phosphate release from the active pocket, 
lowering its affinity for actin (Kovacs et al., 2004).  
 MyoII is important for stabilizing leading edge protrusions and maintaining polarity (Lo 
et al., 2004). Although myosin II is not present in the lamellipodium, its activity influences the 
net rate of cellular protrusion at the leading edge (Ponti et al., 2004; Vicente-Manzanares et al., 
2007). Knockdown of MyoII with small interfering RNAs or treatment of cells with blebbistatin 
reduces actin bundling in the lamellum, whereas the lamellipodium remains intact (Ponti et al., 
2004).   When MyoII is inhibited or deleted, a decrease in actin retrograde flow and in the size of 
adhesions was observed (Ponti et al., 2004; Rottner et al., 1999; Vicente-Manzanares et al., 
2008), highlighting the requirement for MyoII activity in maintaining these structures.  
 While MyoII is dispensable for the assembly and disassembly of nascent adhesions inside 
the lamellipodium, MyoII-mediated tension is essential for the maturation of adhesions as well as 
retraction of the cell rear (Choi et al., 2008; Vicente-Manzanares et al., 2007). The contractile 
actomyosin forces on adhesions enable the recruitment of structural and signaling proteins that 
regulate adhesion maturation as well as disassembly (Gardel et al., 2010; Ponti et al., 2004; 
Wang, 1985). One way that MyoII promote adhesion maturation is through the generation of 
tension, which would induce conformational changes and expose cryptic binding or activation 
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sites in key adhesion components (del Rio et al., 2009; Friedland et al., 2009; Sawada et al., 
2006). Talin binds vinculin when mechanically stretched (del Rio et al., 2009),  and is required to 
transmit MyoII-generated forces to the substratum (Jiang et al., 2003). Because talin’s head 
domain interacts with integrins while its tail binds actin filaments, talin bears the force 
transmitted from the actin cytoskeleton to the matrix. Thus, actomyosin contraction would 
trigger tension-sensitive talin to unfold and increase its binding to vinculin to reinforce the 
adhesion complex (del Rio et al., 2009; Parsons et al., 2010).  Adhesion scaffold proteins, 
paxillin and CAS, can also change conformation to reveal new protein-binding and/or 
phosphorylation sites (Sawada et al., 2006; Zaidel-Bar et al., 2007).  Thus, the resulting protein–
protein interactions and/or phosphorylation would activate these scaffold proteins to recruit 
additional signaling proteins.  
 Another way that MyoII promote adhesion maturation is through the bundling of actin 
filaments, which would result in adhesion proteins at the ends of these actin filaments being 
brought together and being clustered. In turn, this would increase the molecular interactions 
between adhesion proteins and would result in increased integrin avidity (the combined strength 
of multiple integrin–ligand interactions) and signaling (Vicente-Manzanares et al., 2009b).  For 
example, actomyosin-driven binding of vinculin to talin induces the clustering of integrins 
(Humphries et al., 2007).  
 By organizing the actomyosin cytoskeleton and generating contractile forces, MyoII is an 
important regulator of cell migration and its underlying processes. However, the upstream 
molecular signals that mediate actomyosin contractility are not well understood.   
 
Traction and the clutch mechanism 
 As previously mentioned, adhesions generate traction by linking the ECM to actomyosin 
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filaments. In the absence of an adhesion, actin polymerizing at the leading edge flows backward 
because of the resistance from the plasma membrane (Mitchison and Cramer, 1996). Similarly, 
myosin-generated contraction in the lamellum pulls on the actin filaments and contributes to 
rearward movement. Therefore, the net rate of forward protrusion of the leading edge is 
determined by the rate of actin polymerization minus these rearward forces (Parsons et al., 
2010). As actin retrograde flow moves over the adhesions, the latter function as traction points 
that resist the force arising from the rearward flow and shunt the force to the ECM, causing more 
force to be applied to the plasma membrane and leading to forward protrusion. These 
observations have led to the idea that the link between adhesions and actin is regulated by a 
clutch-like mechanism (Fig. 7). However, adhesions components that comprise the clutch do not 
efficiently transmit all of the force to the ECM, as some of them move in a retrograde direction 
with the actin but not at the same rate, pointing to a ‘slippage’ in the actin–adhesion linkage 
(Huttenlocher and Horwitz, 2011; Parsons et al., 2010).  In addition, the strength of connection 
between the actin and integrins could be weak and slip and a highly pliable ECM could move 
under contractile forces.  This complex feedback loop that connects adhesion, contraction, and 
ECM pliability led to the notion that a clutch-like mechanism between adhesions and actin is 
controlling force transmission. When the clutch between adhesions and rearward flowing actin is 
engaged, rates of forward protrusion of the leading edge increase while the adhesions undergo 
force-dependent maturation (Heath and Holifield, 1991; Parsons et al., 2010; Pollard and Borisy, 
2003). 
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Figure 7. Schematic diagram of the molecular clutch.  Focal adhesions act as a molecular 
clutch in migrating cells. a) At the leading edge, actin monomers (blue spheres) assembles onto 
the barbed end of the actin filament (arrow). Dark brown lines are integrin transmembrane 
proteins. (b) When the clutch is disengaged, as actin is assembled (blue spheres), the filament 
moves away from the leading edge due to the force generated by the polymerization of actin and 
the action of myosin motors (yellow oval). This leads to retrograde flow of actin. c) When the 
clutch is engaged, an indirect interaction exists between the actin filament and the ECM through 
FA proteins (red and green). This restrains the filament allowing new actin polymerization to 
propel the protrusion of the leading edge and actomyosin forces to be transmitted through the FA 
into traction on the ECM.  
 
Reprinted from (Gardel, Schneider et al. 2010) 
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Rho GTPases and cell migration   
 The Rho family of small GTPases regulates efficient remodeling of the actin cytoskeleton 
to mediate cell migration (Ridley et al., 2003).  Rho GTPases are essential in propagating 
integrin-mediated responses and, by tightly regulating the dynamics of the actin cytoskeleton, 
provide a key signaling link through which adhesion, spreading, and migration are controlled 
(Lawson and Burridge, 2014). The Rho family of GTPases represents a large portion of the Ras 
superfamily of small GTPases, with an average size of approximately 21 kD (Rossman et al., 
2005). There are approximately 25 Rho family GTPases in mammals; however, the majority of 
these proteins have not been well characterized (Cain and Ridley, 2009). The best-studied ones, 
Rac1, RhoA and CDC42, together regulate adhesion dynamics by directly controlling the 
balance between actin-mediated protrusion and myosin II-mediated contraction (Parsons et al., 
2010). 
 These proteins function as molecular switches and exist in two interconvertible forms: the 
GDP-bound (inactive) and GTP-bound (active) forms (Allende, 1988) (Fig. 8). Active GTPases 
interact with their specific downstream targets to convert upstream molecular signals into 
coordinated arrangements of the actin cytoskeleton, whereas GTP-hydrolysis releases the 
phosphate and inactivates the GTPases (Jaffe and Hall, 2005; Ridley, 2001). The cycling of Rho 
GTPases between an active and inactive state is regulated by guanine nucleotide exchange 
factors (GEFs) and GTPase-activating proteins (GAPs). While GEFs facilitate the release of 
GDP from the GTPases, thus promoting the binding of GTP and the activation of GTPases, 
GAPs stimulate their intrinsic GTPase activity and convert the GTP-bound form of these 
proteins to an inactive GDP-bound state.   
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Figure 8. The Rho GTPase cycle. Rho GTPases cycle between the inactive GDP-bound state 
and active GTP-bound state. Membrane-bound Rho GTPases are activated by guanine nucleotide 
exchange factors (GEFs), which catalyze the exchange of GDP for GTP. Once activated, the 
GTPase can activate a host of downstream effector proteins. Inactivation of the GTPase is 
mediated by GTPase activating proteins (GAPs), which hydrolyze the GTP to produce GDP 
bound to the GTPase.  
Reprinted from Etienne-Manneville and Hall, Nature, 2002 
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 The primary migration-related downstream effectors of the Rho GTPases are molecules 
that regulate actin polymerization, myosin II contraction and thereby adhesions (Huttenlocher 
and Horwitz, 2011). Studies have shown that Rac1 affect the phosphorylation of myosin II via its 
downstream effector, p21-activated kinase (PAK).  Downstream of Rac1, PAK has been show to 
either 1) inhibit myosin light chain kinase, which phosphorylates RLC or 2) phosphorylate RLC 
directly to activate myosin II (Daniels and Bokoch, 1999; Kiosses et al., 1999).  However, the 
mechanism of how myosin II is regulated by Rac1 in migration has not been established.   
 While Rac1 and Cdc42 primarily regulate the assembly of protrusive actin-based 
structures and promote the formation of nascent adhesions near the cell periphery, RhoA 
mediates the assembly of contractile actomyosin stress fibers (Nobes and Hall, 1995; Ridley and 
Hall, 1992a). As such, RhoA is thought to stabilize protrusions and to induce the maturation of 
adhesions (Chrzanowska-Wodnicka and Burridge, 1996; Rottner et al., 1999). To mediate stress 
fiber formation, RhoA activates the protein-Rho-associated kinase (ROCK), which inactivates 
the myosin light chain phosphatase and thereby lead to an activated RLC (Kimura et al., 1996).  
These events activate myosin II, which then associates with actin to form stress fibers (Giuliano 
and Taylor, 1990).  
 The polarized migration of cells across the ECM is a dynamic process that is 
fundamentally linked to the spatially regulated activity of Rho GTPases (Lawson and Burridge, 
2014). In migrating cells, Rho GTPases are spatially and temporally regulated, such that active 
Rac and Cdc42 are localized to the leading edge to induce actin protrusions, while active Rho is 
present at both the front and the rear of the cell (Machacek et al., 2009; Pertz and Hahn, 2004; 
Pertz et al., 2006). Rac1 expression gave rise to the branched dendritic network of actin filaments 
seen in the lamellipodium (Ridley et al., 1992), whereas Cdc42 expression caused an increase in 
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filopodia along the cell periphery that act as probes for sensing the external environment (Nobes 
and Hall, 1995). Actin polymerization is stimulated downstream of these two GTPases via 
downstream effectors such as Wiskott-Aldrich syndrome protein  (WASP), WASP-family 
verprolin homologous protein (WAVE), and PAK. While WAVE and WASP activate the actin 
nucleating complex Arp2/3, PAK leads to LIM kinase activation, which inhibits cofilin-mediated 
breakdown of actin filaments (Ridley, 2011). Based on these studies, Rac1 also uses PAK as an 
effector to modulate actin dynamics. Given the role of RhoA in stimulating actomyosin 
contractility through its effector ROCK, it is not surprising that this GTPase has been implicated 
in regulating the retraction of cell tails (Lawson and Burridge, 2014). 
 This established view of the role of GTPases in polarized migration has however been 
challenged as a result of data generated using Rho GTPase fluorescence resonance energy 
transfer (FRET) biosensors (Kurokawa and Matsuda, 2005; Machacek et al., 2009; Pertz and 
Hahn, 2004; Pertz et al., 2006). Machacek et al. showed that, at the leading edge of mouse 
embryonic fibroblasts (MEFs), RhoA activation precedes Rac and Cdc42 activation both 
spatially and temporally. RhoA activity was also strictly associated with the extent of leading 
edge protrusion, while Rac and Cdc42 are still activated as the protrusion retracts (Machacek et 
al., 2009).  Peak Rac1 activity is observed approximately 40s after peak RhoA activity 
(Machacek et al., 2009), suggesting that RhoA or RhoA-mediated events may be responsible for 
initiating Rac1 activity at the leading edge (Lawson and Burridge, 2014).  
 Based on theses studies, it is clear that Rho GTPases are regulated by an extensive 
crosstalk so that their signaling is coordinated to facilitate cell migration.  Much remains to be 
learned about the role of Rho GTPases and the crosstalk that exists between them in regulating 
cell migration. It would be particularly interesting to learn how the GEFs are responsible for 
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mediating the spatiotemporal activation of Rho and Rac in migrating cells, as well as the 
mechanisms that regulate the spatial distribution of these components. 
Regulators of Rho Family of GTPases 
 The activation of Rho family GTPases is tightly controlled by GEFs. There are 
approximately 69 known proteins in humans that belong to the diffuse B cell lymphoma (Dbl) 
subfamily of Rho GEFs, so named because they share homology with the first identified Rho 
GEF Dbl (Rossman et al., 2005). All Rho family GEFs mediates nucleotide exchange through 
the Dbl homology (DH) and a pleckstrin homology (PH) domain (Rossman et al., 2005). The DH 
domain possesses GEF activity, catalyzing the dissociation of GDP from the GTPases while 
stabilizing the GTPase’s nucleotide-free intermediary conformation (Bos et al., 2007; Cerione 
and Zheng, 1996). Furthermore, mutations in the DH domains of several other proteins in the 
Dbl GEF family, of which Asef2 is a member, have been shown to diminish the ability of these 
GEFs to activate their respective GTPases (Reddy-Alla et al., 2010; Zhu et al., 2000). The PH 
domain is known for lipid, phosphoinositide, and protein-binding, and is believed to localize the 
GEF to the plasma membrane(Harlan et al., 1994). In some cases, the PH domain may also affect 
the activity of the DH domain, since both domains are typically required as the minimum 
functional unit essential for GEF activity (Jaffe and Hall, 2005; Rameh et al., 1997; Schmidt and 
Hall, 2002). Furthermore, some Rho GEFs may contain the Src homology (SH2 and SH3) 
domains, which mediate protein-protein interactions and are commonly found in molecules 
involved in signal transduction. 
 The overabundance of GEFs compared to GTPases adds an additional regulatory 
component to GTPase activity. GEFs contain multiple protein-protein interaction domains that 
are hypothesized to target the GTPases to specific cellular regions, where they can be activated 
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by distinct upstream signals (Rossman et al., 2005). While the function of these small GTPases 
in migration and adhesion dynamics has been studied, the mechanisms by which their specific 
GEFs function is poorly understood. 
The Asef Family of GEFs 
 One important group of GEFs is the Asef (APC-stimulated guanine nucleotide exchange 
factor) family, which belongs to the larger Dbl family of Rho GEFs. The three known GEFs in 
this family are Asef1, Asef2, and collybistin. Whereas Asef1 and Asef2 were initially identified 
based on their interaction with the tumor suppressor adenomatous polyposis coli (APC) (Hamann 
et al., 2007; Kawasaki et al., 2007; Kins et al., 2000), collybistin, which does not bind to APC 
(Kins et al., 2000; Reid et al., 1999), was grouped into the Asef family based on homology 
(Harvey et al., 2004). Collybistin’s most well characterized role has been in neurons as it is 
almost exclusively expressed in the brain (Hamann et al., 2007; Kneussel et al., 2001; Reid et al., 
1999). Thus, this dissertation will not be going into details about collybistin. 
 Asef1- Asef1 or ARHGEF4, was originally identified in a two-hybrid screening of a 
human fetal brain library, using the armadillo binding repeat of APC as bait (Kawasaki, 2000). 
However, Asef1 has a broad expression profile, including brain, colon, and skeletal muscle 
(Hamann et al., 2007; Kawasaki et al., 2007).  This protein contains an APC binding region 
(ABR), a Src homology 3 (SH3) domain, and a conserved DH, and PH domain (Kawasaki, 2000; 
Thiesen et al., 2000). Asef1 exist in an autoinhibitory conformation, in which the ABR-SH3 
domains interacts with the DH domain, and thereby blocking GTPase binding and sterically 
hindering binding of APC to Asef1 (Mitin et al., 2007; Murayama et al., 2007; Zhang et al., 
2012). Asef1 is thought to be an important regulator of cell migration.  Asef1’s GEF activity has 
been shown to promote Rac1 and Cdc42 activation, and its expression increased the phenotype 
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associated with these important regulators of the actin cytoskeleton actin polymerization, and 
cell migration (Kawasaki, 2000; Mitin et al., 2007).  
 Asef2- The Rho Family GEF, Asef2 (or SPATA13), was identified in a database search 
for molecules with homology to Asef1. Like Asef1, Asef2 activates Cdc42 and Rac1, and 
comprises the same domain architecture: a DH, PH, and SH3 domain, with an ABR adjacent and 
N-terminal to the SH3 domain (Hamann et al., 2007; Kawasaki et al., 2007). As a recently 
identified protein, very little is known about Asef2. With no crystal structure data, Asef2’s 
mechanism of activation is believed to mirror that of Asef1, where the ABR-SH3 domain 
mediate the release from autoinhibition by binding to APC (Hamann et al., 2007; Kawasaki et 
al., 2007). This is confirmed as deletion of Asef2’s ABR-SH3 region enhances GTPase 
activation (Hamann et al., 2007; Kawasaki et al., 2007).  Asef2 has been implicated in the 
regulation of cell migration (Bristow et al., 2009), but its function in modulating this process is 
not well understood.  Studies have shown that Asef2 activate both Cdc42 (Bristow et al., 2009; 
Hamann et al., 2007), and Rac (Bristow et al., 2009; Kawasaki et al., 2007), as well as indirectly 
reduce Rho activity (Bristow et al., 2009). Furthermore, Asef2 is highly expressed in colorectal 
tumors, and its deletion in mice resulted in reduction in adenoma growth and the number of 
associated angiogenic blood vessels (Kawasaki et al., 2009), underscoring its role in the 
regulation of cancer cell formation.  
 Because GEFs control the activation of Rho GTPases, they play an active role in 
regulating cell migration. Although Asef2 has been linked to colorectal cancers and cancer cell 
migration, much is left to discover about its downstream effectors  (i.e. myosin II) and the 
molecular mechanism by which they regulate cell migration. Both chapter II and chapter III of 
this thesis, describes a novel role for Asef2-mediated Rac activity in regulating cancer cell 
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migration and actomyosin contraction. 
Hypothesis 
 Cell migration is a coordinated multistep process that include the extension of an actin-
rich protrusion, the formation of cell-matrix adhesions at the leading edge, the forward 
translocation of the cell body, and the release of adhesions along with retraction of the cell rear. 
Coordination of these activities to permit cell movement is tightly controlled by members of the 
Rho family of small GTPases, including Rac, Rho, and Cdc42. While the function of these small 
GTPases in migration and adhesion dynamics has been studied, the mechanism by which their 
specific GEFs function is poorly understood.  In this thesis, we investigate the role of the 
recently identified Rho family GEF, Asef2, and its role in regulating cell migration and its 
underlying processes. As a GEF, Asef2 is known to activate both Rac and Cdc42, and is 
implicated in promoting cell migration. However, little is know about its effect on downstream 
effectors, such as MyoII, and the molecular mechanism by which they regulate cell migration. 
The contractile actomyosin forces mediate adhesion maturation and is essential for rear end 
retraction. However, whereas most studies have linked RhoA to cell contractility, the role of 
other Rho GTPases, including Rac, in regulating actomyosin contraction is currently unknown. 
Since actomyosin contractility is thought to be important for cell migration and Asef2 activates 
Rac, we hypothesize that Asef2 can regulate cancer cell migration in a process involving the 
GTPase Rac and MyoII-dependent contractility. 
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Summary 
 Non-muscle myosin II (MyoII) contractility is central to the regulation of numerous 
cellular processes, including migration. Rho is a well-characterized modulator of actomyosin 
contractility, but the function of other GTPases, such as Rac, in regulating contractility is 
currently not well understood. Here, we show that activation of Rac by the guanine nucleotide 
exchange factor Asef2 (also known as SPATA13) impairs migration on type I collagen through a 
MyoII-dependent mechanism that enhances contractility. Knockdown of endogenous Rac or 
treatment of cells with a Rac-specific inhibitor decreases the amount of active MyoII, as 
determined by serine 19 (S19) phosphorylation, and negates the Asef2-promoted increase in 
contractility. Moreover, treatment of cells with blebbistatin, which inhibits MyoII activity, 
abolishes the Asef2-mediated effect on migration. In addition, Asef2 slows the turnover of 
adhesions in protrusive regions of cells by promoting large mature adhesions, which has been 
linked to actomyosin contractility, with increased amounts of active β1 integrin. Hence, our data 
reveal a new role for Rac activation, promoted by Asef2, in modulating actomyosin contractility, 
which is important for regulating cell migration and adhesion dynamics. 
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Introduction 
 Cell migration is vital for embryonic development and in maintaining homeostasis in the 
adult (Vicente-Manzanares and Horwitz, 2011). Migration also plays a central role in 
pathological disorders, such as atherosclerosis, arthritis and cancer. Therefore, identifying key 
molecular mechanisms that regulate migration is important for developing new therapeutic 
approaches for treating these disorders. Cell migration comprises several underlying processes 
that include establishment of front- back polarity, extension of leading edge protrusions, 
formation of cell-matrix adhesions, translocation of the cell body and retraction of the cell rear 
(Lauffenburger and Horwitz, 1996; Vicente-Manzanares et al., 2005). The formation of integrin- 
based adhesions, which link the actin cytoskeleton to the extracellular matrix (ECM), stabilize 
leading edge protrusions and generate traction forces on the ECM to propel cell movement 
(Beningo et al., 2001; Gardel et al., 2008).  These nascent adhesions can continue to grow and 
mature into large focal adhesions, or they can subsequently disassemble to allow for sustained 
migration (Laukaitis et al., 2001; Webb et al., 2004).  The continuous assembly and disassembly 
of adhesions, termed adhesion turnover, is crucial for cell migration (Webb et al., 2004).  
 MyoII is an actin motor protein that is emerging as a key modulator of cell migration 
through its ability to regulate underlying processes. MyoII is important for stabilizing leading 
edge protrusions and maintaining polarity (Lo et al., 2004).  Moreover, MyoII is essential for the 
maturation of adhesions as well as retraction of the cell rear (Choi et al., 2008; Vicente-
Manzanares et al., 2007).  Structurally, MyoII is composed of two heavy chains (MHC) as well 
as two essential (ELC) and two regulatory (RLC) light chains. Each MHC contains an N-
terminal head domain, a neck region, and a C-terminal a-helical rod domain (Wang et al., 2011).  
The head domains, which contain the motor region, bind to actin and allow MyoII to move along 
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actin filaments by coupling the hydrolysis of ATP to conformational changes. The rod domains 
can associate with other MyoII rod domains to form bipolar filaments. These bipolar filaments 
generate contraction by sliding actin filaments relative to one another, which is a major cellular 
function of MyoII. The activity and function of MyoII is regulated by phosphorylation within the 
RLC (Adelstein and Conti, 1975; Scholey et al., 1980).  Phosphorylation of serine 19 activates 
the motor domain of MyoII and drives actomyosin contractility (Adelstein and Conti, 1975; 
Ikebe, 1989).  Additional phosphorylation on another residue, threonine 18, further enhances 
myosin ATPase activity (Ikebe, 1989). 
 The Rho family of GTPases, which includes Rho, Rac and Cdc42, are molecular switches 
that exist in two interconvertible forms: a GDP-bound form (inactive) and a GTP-bound form 
(active) (Ridley et al., 2003).  Active GTPases interact with their specific downstream targets to 
modulate cell migration, actin polymerization, MyoII contraction and adhesion dynamics 
(Huttenlocher and Horwitz, 2011; Ridley, 2001; Ridley et al., 2003).  Rac and Cdc42 regulate the 
formation of protrusive actin-based structures, lamellipodia and filopodia, respectively, whereas 
Rho is thought to stabilize lamellipodial protrusions (Nobes and Hall, 1995; Ridley and Hall, 
1992b). Rac promotes the assembly of nascent adhesions near the cell periphery, whereas Rho 
activity induces adhesion maturation (Chrzanowska-Wodnicka and Burridge, 1996; Ridley and 
Hall, 1992b; Rottner et al., 1999). Rho activity also stimulates the formation of stress fibers, 
which are contractile F-actin bundles, and promotes actomyosin contractility (Chrzanowska-
Wodnicka and Burridge, 1996; Katoh et al., 2001; Ridley and Hall, 1992b). However, little is 
currently known about the function of the other Rho GTPases, including Rac, in modulating 
actomyosin contraction.  
 The activation of Rho GTPases is regulated by guanine nucleotide exchange factors 
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(GEFs), which facilitate the release of GDP from the GTPases, thus promoting the binding of 
GTP. Asef2 (also known as SPATA13) is a recently identified GEF known to activate both Rac 
and Cdc42 (Hamann et al., 2007; Kawasaki et al., 2007).  Asef2 comprises four domains, 
including an N-terminal adenomatous polyposis coli (APC)-binding region (ABR), an adjacent 
Src homology 3 (SH3) domain, a central Dbl homology (DH) domain that binds GTPases and is 
necessary for its catalytic function, and a pleckstrin homology (PH) domain, which facilitates 
membrane targeting (Hamann et al., 2007; Kawasaki et al., 2007). Binding of the tumor 
suppressor APC to the ABR region has been shown to stimulate the GEF activity of Asef2 by 
releasing it from an auto-inhibited state, where the C-terminus is bound to the ABR-SH3 
domains (Hamann et al., 2007). Asef2 has been implicated in the regulation of cell migration 
(Bristow et al., 2009; Sagara et al., 2009), but its role in modulating this process is not well 
understood.  
 In this study, we demonstrate that Asef2 inhibits cell migration on type I collagen by a 
Rac- and MyoII-dependent mechanism. Asef2 promotes the activation of Rac, which 
subsequently stimulates MyoII contractility. In addition, Asef2 slows adhesion turnover and 
induces large mature adhesions. Therefore, Asef2 modulation of Rac- and MyoII-dependent 
contractility is likely to regulate cell migration by affecting underlying migratory processes such 
as adhesion turnover.  
 
Materials and Methods 
Reagents 
 An anti-Asef2 rabbit polyclonal antibody was made as previously described (Bristow et 
al., 2009). β1 integrin HUTS-4 monoclonal antibody was purchased from Chemicon 
International (Temecula, CA). AIIB2 β1 integrin antibody was kindly provided by Roy Zent 
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(Vanderbilt University, Nashville, TN). Phospho-MLC (S19) polyclonal antibody (clone 3671) 
was obtained from Cell Signaling (Beverly, MA). Phospho-Akt (T308) polyclonal antibody was 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Fibronectin, β-actin monoclonal 
antibody (clone AC-15) and FLAG-M2 monoclonal antibody were from Sigma-Aldrich (St. 
Louis, MO). Paxillin monoclonal antibody was purchased from BD Bioscience Pharmingen (San 
Diego, CA). Alexa-Fluor-555- and Alexa-Fluor-680-conjugated anti-mouse Ig, Alexa-Fluor-647-
conjugated anti-rabbit Ig, and FluoSpheres® carboxylate-modified Nile Red microspheres (Cat. 
No. F-8819) were obtained from Molecular Probes (Eugene, OR). IRDye 800 anti-mouse Ig and 
800 anti-rabbit Ig were purchased from Rockland Immunochemicals (Gilbertsville, PA). Rat-tail 
type I collagen was from BD Biosciences (Bedford, MA). Blebbistatin, NSC23766 and BSA 
were purchased from EMD Bioscience (La Jolla, CA). Aqua Poly/Mount mounting solution (Cat 
# 18606) was obtained from Polysciences, Inc. (Warrington, PA). 
Plasmids 
 GFP-Asef2-encoding cDNA was prepared by cloning full-length Asef2 (Spata13) cDNA 
into pEGFP-C3 vector as previously described (Bristow et al., 2009). mCherry cDNA was a 
generous gift from Roger Tsien (University of California, San Diego, La Jolla, CA). mCherry-
paxillin was kindly provided by Steve Hanks (Vanderbilt University, Nashville, TN). GST-
tagged PBD, wild-type Cdc42 and wild-type Rac1 were kind gifts from Alan Hall (Memorial 
Sloan-Kettering Cancer Center, NY). GST-tagged rhotekin-binding domain and Myc-tagged 
wild-type RhoA were generously provided by Sarita Sastry (University of Texas Medical 
Branch, Galveston, TX). shRNA constructs were generated as previously described (Wegner et 
al., 2008; Zhang and Macara, 2008b) by ligating 64-mer oligonucleotides into GFP-pSUPER 
vector (Asef2 shRNAs) or pSUPER vector (Rac shRNAs). Both target sequences for Asef2 and 
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Rac1 have been previously described (Bristow et al., 2009; Chan et al., 2005). A non-targeting 
shRNA with the sequence 5′-CAGTCGCGTTTGCGACTGG-3′ was used as a control (Saito et 
al., 2007). 
Cell culture 
 HT1080 cells stably expressing GFP or GFP-Asef2 were generated by retroviral 
transduction and selected by incubation with 400 µg/ml G418 as previously described (Bristow 
et al., 2009). Stably expressing GFP and GFP–Asef2 cells were sorted by FACS into populations 
based on their expression level (Bristow et al., 2009). Experiments for this study were performed 
with stable cells expressing low levels of GFP or GFP-Asef2, which were the same cells that 
were used previously (Bristow et al., 2009). Cells were maintained in Dulbecco's modified 
Eagle's medium (DMEM) (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine 
serum (FBS) (Hyclone, Logan, UT) and penicillin-streptomycin (Invitrogen). Wild-type HT1080 
cells were transiently transfected with Lipofectamine™ 2000 (Invitrogen) according to the 
manufacturer's instructions. MDA-MB-231 cells stably expressing GFP or GFP-Asef2 were 
prepared by retroviral transduction as described above for HT1080 cells. Stably expressing GFP 
and GFP-Asef2 MDA-MB-231 cells were maintained in DMEM supplemented with 20% FBS 
and penicillin-streptomycin. 
Microscopy and immunocytochemistry 
 Cells were plated on glass coverslips, which were coated with 5 µg/ml type I collagen or 
2.5 µg/ml fibronectin for 1 hour at 37°C. Following incubation for 2-4 hours at 37°C to permit 
attachment, cells were fixed for 20 minutes with 2-4% paraformaldehyde and 4% sucrose in 
phosphate-buffered saline (PBS). In some experiments, cells were fixed by incubation with ice-
cold methanol for 10 minutes at -20°C. Cells were permeabilized for 5 minutes at 23°C with 
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0.2% (v/v) Triton X-100, and incubated with either 20% goat serum or 10% BSA in PBS for 1 
hour at 23°C to block non-specific binding. After blocking, cells were incubated with the 
indicated primary and fluorescently conjugated secondary antibodies, which were diluted in 
either 5% goat serum or 2% BSA in PBS, for 1 hour at 23°C. Following each step, coverslips 
were washed three times with PBS. Coverslips were mounted on microscope glass slides (Fisher 
Scientific, Pittsburgh, PA) with Prolong Gold Antifade reagent (Invitrogen, Carlsbad, CA). 
Images were acquired with either an inverted Olympus IX71 microscope (Melville, NY) 
equipped with a Retiga EXi CCD camera (QImaging, Surrey, BC) and a PlanApo 60× OTIRFM 
objective (NA 1.45) or a Quorum WaveFX spinning disk confocal system with a Nikon Eclipse 
Ti microscope, a Hamamatsu ImageEM-CCD camera, and a PlanApo 60× TIRF objective (NA 
1.49). To visualize GFP, an Endow GFP Bandpass filter cube (excitation HQ470/40, emission 
HQ525/50, Q495LP dichroic mirror) was used. Alexa Fluor® 555 and mCherry were observed 
using a TRITC/Cy3 cube (excitation HQ545/30, emission HQ610/75, Q570LP dichroic mirror), 
and Alexa Fluor® 647 (far-red) was observed with a Cy5™ cube (excitation HQ620/60, 
emission HQ700/75, Q660LP dichroic mirror). The background-subtracted integrated fluorescent 
intensity was normalized to cell area (average intensity). 
 For quantification of phosphorylated (S19) MyoII and total MyoII, the average 
fluorescence intensity was obtained by normalizing the background-subtracted integrated 
fluorescence intensity in individual cells to the unit area using MetaMorph software. For 
quantification of the amount of active and total β1 integrin in adhesions, the average 
fluorescence intensity was measured by normalizing the background-subtracted integrated 
fluorescence intensity in individual adhesions to the unit area with MetaMorph software.  
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In-cell western assay 
 At total of 104 cells were allowed to adhere for 2-4 hours at 37°C to 96-well plates that 
were coated with 5 µg/ml type I collagen. After attachment, cells were incubated for 20 minutes 
at 23°C with 4% paraformaldehyde in PBS and permeabilized for 5 minutes at 23°C with 0.2% 
(v/v) Triton X-100. Cells were then incubated with 5% BSA in PBS (blocking solution) for 1 
hour at 23°C to block non-specific binding. Following blocking, cells were incubated with the 
indicated primary and fluorescently conjugated secondary antibodies in blocking solution for 1 
hour at 23°C. Cells were washed three times with PBS after each incubation. After the final 
wash, 96-well plates were aspirated and inverted to remove the residual wash solution and 
scanned with a LI-COR® Odyssey® infrared imaging system (LI-COR Biosciences, Lincoln, 
NE). The background-subtracted mean integrated intensities were obtained using Odyssey® 3.2 
ICW module software. Background fluorescence was determined from cells that were incubated 
with secondary antibodies alone.  
Migration assay 
 Cells were allowed to adhere for 1-2 hours at 37°C to tissue culture dishes that were 
coated with 5 µg/ml type I collagen or 2.5 µg/ml fibronectin. Phase-contrast images were 
acquired every 5 minutes for up to 6 hours using MetaMorph software (Molecular Devices, Inc. 
Sunnyvale, CA), interfaced with a Lambda 10-2 automated controller (Sutter Instruments), and 
an Olympus IX71 microscope with a 10× objective (NA 0.3). During imaging, cells were 
maintained in SFM4MAb™ media (Hyclone, Logan, UT) supplemented with 2% FBS (imaging 
media). In some experiments, cells were pre-treated with 20 µM blebbistatin or DMSO (vehicle 
control) for 1 hour at 37°C. After pre-incubation, phase contrast images were acquired every 5 
minutes for 6 hours. Then, blebbistatin was removed, cells were washed with PBS, fresh imaging 
	   43	  
medium was added, and cells were imaged for an additional 6 hours. MetaMorph software was 
used to track cell movement, and the migration speed was calculated by dividing the total 
distance that cells moved in microns by the time. Wind-Rose plots were obtained by setting the 
X-Y coordinates of cell tracks to a common origin. 
Analysis of adhesion turnover 
 Stably expressing GFP and GFP-Asef2 cells were transfected with 1 µg of mCherry-
paxillin-encoding cDNA. After 24 hours, cells were plated on microscopy dishes coated with 
type I collagen and allowed to adhere for 1-2 hours at 37°C. Time-lapse fluorescence images 
were acquired at 15-second intervals, and t1/2 values for adhesion assembly and adhesion 
disassembly were calculated as previously described (Bristow et al., 2009; Webb et al., 2004).  
Rho family GTPase activity assays 
 GFP and GFP-Asef2 stably expressing cells were transfected with 3 µg cDNA encoding 
FLAG-Rac1, FLAG-Cdc42 or Myc-RhoA. After 24 hours, cells were lysed and assayed for 
active Rac, Cdc42 and Rho as previously described (Bristow et al., 2009; Ren et al., 1999). In 
some experiments, wild-type HT1080 cells were co-transfected with 2 µg FLAG–Rac1 and 2 µg 
of either Asef2 shRNA 1 or NT shRNA. Three days later, lysates from cells were collected and 
analyzed as described above. 
Traction force measurements 
 Polyacrylamide (PAA) gels embedded with 1.0 µm FluoSpheres® fluorescent beads were 
prepared on rectangular glass coverslips as previously described (Sabass et al., 2008).  PAA gels 
were incubated with 140 µg/ml type I collagen for 4 hours at 23°C. The thickness of the PAA 
gels was ~30 µm, and the Young’s modulus of the gels was 15.6 kPa as calculated previously 
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(Sabass et al., 2008; Yeung et al., 2005).  A total of 5x103 GFP or GFP-Asef2 stably expressing 
cells were incubated with PAA gels coated with type I collagen for 2 hours at 37°C to allow cells 
to adhere. For each cell of interest, a DIC image of the cell and a fluorescence image of the 
FluoSpheres® beads with the attached cell were taken. Then, the cell of interest was dissociated 
from the PAA gel by trypsinization, and a fluorescence image of the FluoSpheres® beads were 
acquired. Images were acquired using the Quorum WaveFX spinning disk confocal system with 
a Nikon Eclipse Ti microscope, a Hamamatsu ImageEM-CCD camera, and a Plan Fluor 40X 
objective (NA 1.3). FluoSpheres® fluorescent beads were imaged using a 561 nm laser and a 
593/40 nm BrightLine® single-band bandpass emission filter (Semrock, Rochester, NY). 
Traction force maps were generated from the acquired images using LIBTRC software (Dembo 
and Wang, 1999), which was developed by Micah Dembo (Boston University, Boston, MA).  
FRET imaging and analysis  
 Wild-type HT1080 cells were co-transfected with the Raichu-Rac FRET probe (a kind 
gift from Michiyuki Matsuda, Kyoto University, Kyoto, Japan) and either mCherry-Asef2 or 
mCherry. After 24 hours, cells were plated on glass coverslips, which were coated with 5 µg/ml 
type I collagen, for 1 hour at 37°C. Cells were fixed by incubation for 15 minutes at 23°C with a 
4% paraformaldehyde (wt/vol) PBS solution containing 0.12 M sucrose. Coverslips were then 
mounted onto glass slides using Aqua Poly/Mount mounting solution. Images were acquired 
with a Zeiss LSM 510 Meta inverted confocal microscope using a Plan-Apochromat 63× 
objective (NA 1.4). CFP, YFP and mCherry fluorophores were excited with a 458, 514 and 543 
nm laser, respectively. Images were collected using the following emission filters: CFP, BP 475–
525 nm; YFP, LP 530 nm; and mCherry, LP 560 nm. mCherry images were used to identify cells 
expressing either mCherry–Asef2 or mCherry. CFP and YFP images were acquired both before 
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and after bleaching YFP (the FRET acceptor) within an ROI. YFP images were taken to confirm 
that YFP was bleached within the ROI. CFP images were used to calculate the FRET efficiency 
of the active Rac FRET probe using the following equation: (CFPPost−CFPPre)/CFPPost×100. 
CFPPost is the average intensity of CFP in the ROI after bleaching YFP with the 514 nm laser, 
and CFPPre is the average intensity of CFP in the ROI before bleaching YFP with the 514 nm 
laser. The average FRET efficiency of cells expressing mCherry-Asef2 was then compared to 
cells expressing mCherry using a Student's t-test statistical analysis.  
Flow cytometry  
 GFP and GFP-Asef2 stably expressing cells were cultured on 5 µg/ml dishes coated with 
type I collagen for 18 hours at 37°C. Cells were then trypsinized (2.5% trypsin without EDTA) 
and resuspended in ice-cold Opti-MEM (GIBCO) containing 2% FBS (cell-sorting buffer). Cell 
suspensions (2.5×105 cells) were incubated with primary HUTS-4 antibody (1:500 dilution in 
cell-sorting buffer) for 30 minutes at 4°C followed by secondary Alexa Fluor® 555 antibody 
(1:1000 dilution in cell-sorting buffer) for 20 minutes at 4°C. To determine non-specific binding, 
an equal amount of cell suspension was incubated with secondary antibody alone. Cells were 
washed three times with ice-cold cell-sorting buffer following each incubation. After the final 
wash, cells were resuspended in 500 µl of cell-sorting buffer and subjected to flow cytometry. 
For total β1 integrin staining, cells were incubated with AIIB2 antibody (1:50 dilution) and 
subjected to flow cytometry as described above. AIIB2 antibody binds to the extracellular 
domain of β1 integrin. Histograms were generated using FlowJo software. 
Collagen gel contraction assay  
 Type I collagen gel contraction assays were performed as previously described (Tovell et 
al.; Vernon and Gooden, 2002). Briefly, type I collagen was mixed with DMEM to a final 
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concentration of 1.5 µg/ml and the pH was adjusted to 7.4 with 1 M NaOH. Cells in DMEM with 
10% FBS were added to the type I collagen mixture to a final concentration of 2.5×105 cells per 
gel. This mixture was added to 24-well cell culture plates (Costar, Corning NY) and allowed to 
solidify by incubation for 1 hour at 37°C. Serum-free DMEM was added to the wells, and the 
collagen gels were gently detached using a pipette tip. The gels were incubated for 14 hours at 
37°C, and then the diameter of the gels were measured. In some experiments, cells were 
incubated with 100 µM NSC23766 or DMSO as a vehicle control for 14 hours at 37°C. 
 
Results 
Asef2 inhibits cell migration on type I collagen  
 We have previously shown that Asef2 promotes cell migration when cells are plated on 
fibronectin (Bristow et al., 2009).  Indeed, in our previous study, the migration speed of HT1080 
cells stably expressing GFP-Asef2 was increased 1.6-fold compared to control cells stably 
expressing GFP. In this study, to further investigate the role of Asef2 in regulating cell 
migration, we plated GFP-Asef2 and GFP stably expressing cells on type I collagen. These cells 
express low levels of GFP-Asef2 (less than 3-fold over endogenous) (Bristow et al., 2009). 
Intriguingly, GFP-Asef2 cells, plated on type I collagen, migrated significantly more slowly than 
GFP control cells (Fig. 9A), suggesting that Asef2 impairs migration on type I collagen. Given 
that these results were surprising, we performed side-by-side migration experiments with GFP 
and GFP–Asef2 stably expressing cells plated on fibronectin or type I collagen. Consistent with 
our previous results, GFP-Asef2 promoted migration on fibronectin, but inhibited migration on 
type I collagen, indicating that Asef2 differentially affects migration on these substrates (Fig. 
10A). We continued to probe the function of Asef2 in regulating migration on type I collagen by 
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transiently transfecting wild-type HT1080 cells with GFP–Asef2 or GFP as a control. As with 
the stable cells, expression of GFP- Asef2 resulted in a decrease in migration speed as compared 
to that observed with GFP-expressing cells (Fig. 10B). We then examined the effect of Asef2 on 
migration on type I collagen in another cell type by generating MDA-MB-231 cells that stably 
expressed GFP-Asef2 or GFP as a control. As with HT1080 cells, stable expression of GFP-
Asef2 in MDA-MB-231 led to a significant reduction in migration speed as compared to that 
observed with GFP-expressing cells (Fig. 11A), suggesting Asef2 inhibits migration on type I 
collagen.  
 We further probed the role of Asef2 in regulating migration on type I collagen by 
knocking down endogenous expression of the protein using two short hairpin RNA (shRNA) 
constructs. Although these shRNAs had previously been shown to be effective (Bristow et al., 
2009), we confirmed their ability to knockdown Asef2. When wild-type HT1080 cells were 
transfected with Asef2 shRNA1 or Asef2 shRNA2, endogenous expression of Asef2 was 
decreased by ~65% compared with empty pSUPER vector or a non-targeting shRNA (NT 
shRNA) (Fig. 9B). Transfection of HT1080 cells with the two Asef2 shRNAs resulted in a 1.3-
fold increase in migration speed compared to that observed with cells transfected with pSUPER 
or NT shRNA (Fig. 9C), demonstrating that knockdown of endogenous Asef2 enhances 
migration on type I collagen. Collectively, our results suggest an interesting new role for Asef2 
in regulating migration on type I collagen. 
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Figure 9. Asef2 impairs cell migration on type I collagen. (A) GFP and GFP–Asef2 stably 
expressing HT1080 cells were plated on tissue culture dishes coated with type I collagen and 
imaged using time- lapse microscopy. The migration paths of individual cells were tracked and 
analyzed. Left, Rose plots of the migration tracks for five cells. Right, quantification of the 
migration speed for GFP and GFP–Asef2 cells. Error bars represent the s.e.m. for 59–63 cells 
from three independent experiments. *P<0.0001. (B) Left, wild-type HT1080 cells were 
transfected with empty pSUPER vector, a non- targeting shRNA (NT shRNA), or Asef2 
shRNAs. Cell lysates were immunoblotted for Asef2 to determine endogenous expression of this 
protein and for b-actin as a loading control. Right, quantification of the amount of endogenous 
Asef2 in cells transfected with the indicated constructs. Error bars represent the s.e.m. from five 
independent experiments. *P<0.0001. 
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Figure 9 Cont’d. Asef2 impairs cell migration on type I collagen. (C) Wild-type HT1080 cells 
were transfected with empty pSUPER vector, a NT shRNA or Asef2 shRNAs and used in 
migration assays 3 days later. Left, Rose plots of migration tracks for cells transfected with these 
constructs. Right, quantification of the migration speed for cells transfected with empty pSUPER 
vector, a NT shRNA, or Asef2 shRNAs. Error bars represent the s.e.m. for at least 40 cells from 
three independent experiments. *P<0.0001.  
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Figure 10. Asef2 regulates migration on fibronectin and type I collagen through distinct 
molecular mechanisms. (A) GFP and GFP-Asef2 stable HT1080 cells were plated on 
fibronectin or type I collagen-coated tissue culture dishes and imaged using time-lapse 
microscopy. The migration of individual cells was tracked and analyzed. Quantification of the 
migration speed for cells plated on fibronectin and type I collagen is shown. Error bars represent 
S.E.M. for at least 59 cells from three independent experiments (*p < 0.0001, **p < 0.007). (B) 
Wild-type HT1080 cells were transiently transfected with GFP or GFP-Asef2 and used in 
migration assays. Quantification of the migration speed for GFP and GFP-Asef2 expressing cells 
is shown. Error bars represent S.E.M. for at least 49 cells from three independent experiments 
(*p < 0.0001).  
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Figure 11. Asef2 impairs cell migration in MDA-MB-231 cells. (A) GFP and GFP-Asef2 
stable MDA-MB-231 cells were plated on type I collagen-coated tissue culture dishes and used 
in migration assays. Left, Rose plots of migration tracks for five GFP and GFP-Asef2 expressing 
cells are shown. Right, quantification of the migration speed for GFP and GFP-Asef2 cells is 
shown. Error bars represent S.E.M. for at least 62 cells from three separate experiments (*p < 
0.0001).  
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Rac activity is enhanced by Asef2  
 We next investigated the mechanism by which Asef2 impairs migration on type I 
collagen. In initial experiments, we examined the effect of Asef2 on the activity of the Rho 
family GTPases Rac, Cdc42 and Rho using a pulldown assay. In this assay, GFP and GFP–Asef2 
cells were plated on type I collagen, and GST- tagged binding domains from effectors were used 
to detect the active forms of these small GTPases from cell lysates. Interestingly, GFP–Asef2 
expression did not significantly affect the level of active Cdc42 or Rho (Fig. 12A). In contrast, 
the amount of active Rac was increased ~1.8-fold in GFP–Asef2 cells compared to GFP controls 
(Fig. 12A). Moreover, knockdown of endogenous Asef2 in wild-type HT1080 cells by 
transfection with Asef2 shRNA 1 caused a decrease in Rac activity compared to that observed 
with cells transfected with NT shRNA (Fig. 12B). Taken together, these results suggest that 
Asef2 promotes the activation of Rac, but not Cdc42 and Rho, when cells are plated on type I 
collagen. 
 To further demonstrate that Asef2 increases Rac activity, we used a Raichu-Rac 
fluorescence resonance energy transfer (FRET) probe. Raichu-Rac is composed of yellow 
fluorescent protein (YFP), the p21-binding domain (PBD) from the Rac effector p21-activated 
kinase (PAK), Rac, and cyan fluorescent protein (CFP) (Itoh et al., 2002). Upon activation, Rac 
binds to PBD, which brings YFP and CFP in close enough proximity to undergo FRET (Itoh et 
al., 2002). To perform acceptor photo-bleaching FRET, we expressed the Raichu-Rac probe and 
either mCherry–Asef2 or mCherry as a control in HT1080 cells and photo-bleached a region of 
interest (ROI) with a 514 nm laser. With acceptor photo-bleaching, when YFP (FRET acceptor) 
is photo-bleached, the intensity of CFP (FRET donor) increases if FRET occurs. YFP images, 
taken pre- and post- bleaching, demonstrated that YFP was effectively photo- bleached (Fig. 
12C). CFP images that were acquired before (pre) and after photo-bleaching YFP (post) showed 
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an increase in the intensity of CFP emission in Asef2-expressing cells (Fig. 12C), indicating 
FRET had occurred. Quantification revealed that Asef2 did indeed increase the FRET efficiency 
of the Raichu-Rac probe (Fig. 12C), showing that Asef2 significantly enhances the level of 
active Rac in cells.  
 To determine whether Asef2 inhibition of migration on type I collagen was dependent on 
Asef2 GEF activity, we generated a GEF deficient mutant. We mutated lysine 382 within the DH 
domain of Asef2 to alanine (K382A). Mutation of this residue in the related GEF collybistin 
impaired its GEF activity (Reddy-Alla et al., 2010). In an active Rac pulldown assay, GFP-Asef2 
expression significantly enhanced the level of active Rac in HT1080 cells compared to GFP 
control cells (Fig. 12D). In contrast, expression of the Asef2 GEF mutant (GFP-Asef2- K382A) 
did not increase the amount of active Rac (Fig. 12D), indicating that the K382A mutation 
abolished GEF activity in Asef2. The migration speed of cells expressing GFP-Asef2-K382A 
was comparable to that observed in cells expressing GFP, whereas expression of GFP-Asef2 led 
to a significant decrease in migration speed (Fig. 12E). Thus, the GEF activity of Asef2 is crucial 
for the function of Asef2 in impairing migration on type I collagen. 
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Figure 12. Asef2 enhances activation of Rac and regulates migration through its GEF 
activity. (A) Upper, the active forms of Rac, Cdc42 and Rho were pulled down from lysates of 
GFP and GFP–Asef2 cells plated on type I collagen. The total level of these GTPases is shown 
as a control. Lower, quantification of the amount of active Rac, Cdc42, and Rho from at least 
three separate experiments. Error bars represent the s.e.m. *P<0.006, n.s. denotes no statistically 
significant difference. (B) Left, wild-type HT1080 cells were transfected with NT shRNA or 
Asef2 shRNA 1, and 3 days later, active Rac was pulled down from lysates. The total level of 
Rac is shown as a control. Right, quantification of the amount of active Rac from three 
independent experiments. Error bars represent the s.e.m. *P<0.0002.  
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Figure 12 Cont’d. Asef2 enhances activation of Rac and regulates migration through its 
GEF activity. (C) HT1080 cells co-expressing the Raichu-Rac FRET probe and either mCherry 
or mCherry–Asef2 were subjected to acceptor photo- bleaching FRET analysis. Left, images of 
YFP and CFP before (Pre) and after (Post) photo-bleaching YFP with a 514 nm laser. The white 
square boxes denote the ROI where YFP was bleached. High-magnification images of the CFP 
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intensity in the bleached ROIs (Zoom). CFP intensities are depicted on a pseudo-color scale in 
which lower intensity values are displayed in cool colors, whereas higher intensity values are 
displayed in warm colors. Scale bars: 5 µm (CFP panels), 2 µm (‘Zoom’ panels). Right, 
quantification of the average FRET efficiency of the Raichu-Rac FRET probe in mCherry and 
mCherry–Asef2 expressing cells. Error bars represent s.e.m. for 93–107 cells from three separate 
experiments. *P<0.0001. (D) Left, the active form of Rac was pulled down from lysates of wild-
type HT1080 cells that were co-transfected with FLAG–Rac and either GFP, GFP–Asef2, or 
GFP–Asef2 in which lysine 382 in the DH domain was mutated to alanine (GFP– Asef2-
K382A). Right, quantification of the amount of active Rac from blots from four independent 
experiments. Error bars represent the s.e.m. *P<0.03, **P<0.01. (E) HT1080 cells were 
transfected with GFP, GFP–Asef2 or GFP–Asef2-K382A and used in migration assays. Left, 
Rose plots of migration tracks of transfected cells. Right, quantification of the migration speed of 
cells transfected with GFP, GFP–Asef2 or GFP–Asef2-K382A. Error bars represent the s.e.m. 
for at least 70 cells from six independent experiments. *P<0.0001.  
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Asef2 promotes larger adhesions that turn over slowly on type I collagen  
 Because adhesion assembly and disassembly (adhesion turnover) at the leading edge of 
cells is an important process that underlies migration, we hypothesized that the slower migration 
promoted by Asef2 resulted from impaired adhesion turnover. We began to test this hypothesis 
by immunostaining GFP and GFP–Asef2 stably expressing HT1080 cells for paxillin, a well-
known adhesion marker. In GFP–Asef2 cells, the adhesions appeared larger than those observed 
in GFP cells, suggesting that adhesion turnover was slower in these cells (Fig. 13A). Indeed, 
when adhesion turnover was quantified using an assay that we previously developed (Webb et 
al., 2004), the t1/2 values for adhesion assembly and disassembly were increased by ~2-fold and 
1.5-fold, respectively, in GFP–Asef2 cells compared with GFP control cells (Fig. 13B). These 
results indicate that adhesions are assembling and disassembling significantly more slowly in 
GFP–Asef2 cells. 
 Because binding of active (high-affinity state) integrins to the ECM initiates the assembly 
of adhesions (Hynes, 1992; Welf et al., 2012).  Asef2 could affect adhesion turnover by altering 
the amount of active integrins at the cell membrane. To examine cell surface levels of active β1 
integrin, a major integrin that binds to type I collagen, GFP and GFP–Asef2 cells were incubated 
with HUTS-4 antibody and subjected to flow cytometry. HUTS-4 antibody specifically binds to 
the activated conformation of β1 integrin (Luque et al., 1996). The amount of cell-surface active 
β1 integrin was increased ~3-fold in GFP–Asef2 cells compared with GFP controls, whereas the 
total level of β1 integrin was not significantly different (Fig. 13C). Moreover, as determined by 
total internal reflection microscopy (TIRF), the level of active β1 integrin in adhesions was 
significantly higher in GFP–Asef2 cells than in GFP cells, whereas the amount of total β1 
integrin was comparable in these cells (Fig. 13D). Interestingly, the Asef2- promoted increase in 
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the level of active β1 integrin in adhesions was diminished by treatment of GFP–Asef2 cells with 
the Rac specific inhibitor NSC23766 (Fig. 14). NSC23766 specifically blocks Rac binding and 
activation by its GEFs (Gao et al., 2004). Furthermore, the amount of active β1 integrin in 
adhesions was increased in GFP–Asef2 stably expressing MDA-MB-231 cells compared to GFP 
control cells (Fig. 15). In addition, knockdown of endogenous Asef2 in HT1080 cells with Asef2 
shRNA 1 decreased the level of active β1 integrin in adhesions compared to cells transfected 
with NT shRNA (Fig. 13E). Thus, our data suggest that activation of Rac by Asef2 slows the 
turnover of adhesions by increasing the level of active β1 integrin in these structures. 
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Figure 13. Asef2 increases levels of active β1 integrin in adhesions and slows adhesion 
turnover. (A) Upper, GFP and GFP–Asef2 cells were immunostained for paxillin, a well- 
characterized adhesion marker. Lower, higher magnification images of the boxed regions in the 
upper panels. Scale bar: 5 µm. (B) GFP and GFP–Asef2 cells were transfected with mCherry–
paxillin and used in adhesion turnover assays. Quantification of the apparent t1/2 for adhesion 
assembly and the t1/2 for adhesion disassembly. Error bars represent the s.e.m. for 20–25 
adhesions from four or five cells from three separate experiments. *P<0.0001. (C) Left, GFP and 
GFP– Asef2 cells were incubated with HUTS-4 antibody, which recognizes active β1 integrin, 
and fluorescently conjugated secondary antibody. HUTS-4 antibody binding to active β1 integrin 
on cells was measured using flow cytometry, and histograms are shown. Right, the total level of 
β1 integrin on GFP and GFP–Asef2 cells were assessed using AIIB2 antibody and flow 
cytometry. Histograms are shown. Lower, quantification of HUTS-4 (active β1 integrin) and 
AIIB2 (total β1 integrin) binding to GFP and GFP–Asef2 cells. Error bars represent s.e.m. from 
three separate experiments. *P,0.0001.  
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Figure 13 Cont’d. Asef2 increases levels of active β1 integrin in adhesions and slows 
adhesion turnover. (D) Left, GFP and GFP–Asef2 cells were immunostained for active or total 
β1 integrin and subjected to TIRF microscopy. Scale bar: 5 µm. Right, quantification of the 
amount of active β1 integrin (upper panel) and total β1 integrin (lower panel) in adhesions from 
GFP and GFP–Asef2 cells. Error bars represent s.e.m. from at least 60 adhesions from three 
separate experiments. *P<0.002. (E) Left, wild-type HT1080 cells were transfected with NT 
shRNA or Asef2 shRNA 1. After 3 days, cells were immunostained for active or total β1 integrin 
and subjected to TIRF microscopy. Scale bar: 5 µm. Right, quantification of the amount of active 
and total β1 integrin in adhesions from NT shRNA and Asef2 shRNA 1 transfected cells. Error 
bars represent s.e.m. from at least 59 adhesions from three separate experiments. *P<0.0003. For 
panels D and E, active and total β1 integrin images are shown in pseudo-color coding. For panels 
C–E, n.s. denotes no statistically significant difference. 
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Figure 14. Asef2 regulates the levels of β1 integrin through Rac. (B) GFP and GFP-Asef2 
stable HT1080 cells were treated with the Rac inhibitor NSC23766 or DMSO, immunostained 
for active or total β1 integrin, and imaged with TIRF microscopy. Quantification of the amount 
of active (left panel) and total (right panel) β1 integrin in adhesions in GFP and GFP-Asef2 cells 
is shown. Error bars represent S.E.M. from at least 56 adhesions from three separate experiments 
(*p = 0.0004; **p < 0.03; ***p < 0.003). “n.s.” denotes no statistically significant difference.  
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Figure 15.  Asef2 increases the amount of active β1 integrin in MDA-MB-231 cells to 
regulate migration and contractility. (B) GFP and GFP-Asef2 stable MDA-MB-231 cells, 
plated on type I collagen, were immunostained for active or total β1 integrin and were imaged 
with TIRF microscopy. Quantification of the amount of active (left panel) and total (right panel) 
β1 integrin in adhesions in GFP and GFP-Asef2 cells is shown. Error bars represent S.E.M. from 
at least 83 adhesions from three independent experiments (*p < 0.0001). 	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Traction force and cell contractility are enhanced by Asef2  
 Because a major role for adhesions is to transmit traction forces to the ECM (Balaban et 
al., 2001; Beningo et al., 2001), we hypothesized that Asef2 functions by increasing the traction 
force in cells. Using traction force microscopy, we created vector maps of the traction stresses 
(force per unit area) that were generated by GFP and GFP–Asef2 stably expressing HT1080 
cells. The vector maps showed that the traction stresses were significantly higher in GFP–Asef2 
cells compared to GFP controls (Fig. 16A). Relatively high traction stresses were observed 
throughout GFP– Asef2 cells, but the largest stresses were seen at the cell edge. Quantification 
revealed that the average traction stress was ~4-fold greater in GFP–Asef2 cells compared with 
GFP cells. These results demonstrate that Asef2 dramatically enhances traction stresses in cells.  
 Previous work has shown that actomyosin contractility promotes the maturation of 
adhesions (Choi et al., 2008; Chrzanowska-Wodnicka and Burridge, 1996). Given that Asef2 
induces larger adhesions as well as slowing adhesion turnover, it could function in regulating 
contractility. To examine the effect of Asef2 on contractility, we used a gel contraction assay 
(Tovell et al., 2011; Vernon and Gooden, 2002). In this assay, GFP and GFP–Asef2 cells were 
incubated in type I collagen gels for 14 hours to allow for contraction of the gels by cells. 
Contractility was assessed by measuring the diameter of gels at the beginning and at the end of 
the incubation period. At the end of the assay, the diameters of gels that contained GFP–Asef2 
cells were significantly reduced compared to those containing GFP cells (Fig. 16B), indicating 
greater gel contraction by Asef2 cells. When contraction was quantified by expressing the gel 
diameters at the end of the assay (contracted gels) as a percentage of the original gel diameters, 
gels containing GFP–Asef2 stable HT1080 cells were decreased by ~40% compared to those 
containing GFP cells (Fig. 16B). Similar results were observed with GFP–Asef2 stably 
expressing MDA-MB-231 cells (Fig. 17).  In addition, knockdown of endogenous Asef2 in  
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Figure 16. Traction force and cell contractility are significantly increased by Asef2. (A) 
GFP and GFP–Asef2 stably expressing HT1080 cells were cultured in polyacrylamide (PAA) 
gels, embedded with FluoSpheresH fluorescent beads, for traction stress measurements. Upper, 
DIC images of GFP and GFP–Asef2 cells in PAA gels. Lower, color-coded vector maps show 
traction stresses produced by these cells. In the vector maps, the length and orientation of arrows 
indicate the magnitude and direction of traction stresses. Right, quantification of average traction 
stresses generated by GFP and GFP–Asef2 cells. Error bars represent the s.e.m. for 25 cells from 
at least three individual experiments. *P<0.003. (B) GFP and GFP–Asef2 stable HT1080 cells 
were embedded in type I collagen gels, and gels were incubated for 14 hours at 37°C to allow for 
contraction. Left, images of contracted gels with GFP and GFP–Asef2 cells. The gel 
circumferences are outlined with dotted white lines. Right, at the end of the contraction assay, 
the diameter of the gels was measured and expressed as a percentage of the original gel diameter 
(before contraction). Error bars represent s.e.m. from three independent experiments. *P<0.0002.  
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Figure 17. Asef2 leads to increased cell contractility in MDA-MB-231 cells.  (C) GFP and 
GFP-Asef2 stable MDA-MB-231 cells were used in type I collagen gel contraction assays. Left, 
images of contracted gels with GFP and GFP-Asef2 cells are shown. Right, quantification of gel 
contraction for GFP and GFP-Asef2 is shown. Error bars represent S.E.M. from three 
independent experiments (*p < 0.0009).  
 
 
 
	  
Figure 18. Asef2 knockdown inhibits cell contractility. (C) Wild-type HT1080 cells were 
transfected with NT shRNA or Asef2 shRNA 1 and used in type I collagen gel contraction assays 
3 days later. Left, images of contracted gels with NT shRNA and Asef2 shRNA 1 transfected 
cells. Right, quantification of gel contraction for cells transfected NT shRNA or Asef2 shRNA 1. 
Error bars represent s.e.m. from three independent experiments. *P<0.0005. 
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HT1080 cells led to an increase in gel diameters compared to those observed with NT shRNA 
transfected cells, indicating that Asef2 knockdown reduced gel contraction (Fig. 18). Taken 
together, these results demonstrate that Asef2 increases contractility in cells.  
Asef2 regulates migration by increasing MyoII activity  
 As our results show that Asef2 increases contractility, and MyoII activity is known to 
modulate contractility in cells (Adelstein and Conti, 1975; Scholey et al., 1980), we next 
examined the role of MyoII in mediating Asef2 function. MyoII activity is regulated by 
phosphorylation of S19 in its RLCs, and thus, the phosphorylation state of this residue can be 
used to assess MyoII activity (Ikebe, 1989; Matsumura et al., 1998). We determined the level of 
active MyoII in GFP and GFP–Asef2 stably expressing HT1080 cells by immunostaining with 
antibody against MyoII phosphorylated at S19 (phospho-S19 MyoII) and imaging with 
fluorescence microscopy. As shown in Fig. 19A, the amount of phospho-S19 MyoII (p-S19 
MyoII; active MyoII) was greater in GFP–Asef2 stably expressing HT1080 cells than in GFP 
cells. When the fluorescence intensity of active MyoII was quantified for individual cells, the 
amount of active MyoII was increased ~1.5-fold in GFP–Asef2 cells compared to that observed 
in GFP cells, whereas the level of total MyoII was not significantly different in these cells (Fig. 
19A). Moreover, the amount of active MyoII was increased in GFP–Asef2 stable MDA-MB-231 
cells compared with GFP controls (Fig. 20). Conversely, knockdown of endogenous Asef2 in 
HT1080 cells led to a decrease in the level of active MyoII (Fig. 19B). Thus, these results 
indicate that Asef2 increases the level of active MyoII in cells.  
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Figure 19. Asef2 increases phosphorylation of MyoII at S19. (A) Left, GFP and GFP–Asef2 
stably expressing HT1080 cells were immunostained for MyoII phosphorylated at S19 (p-S19 
MyoII) or total MyoII. Scale bar: 15 µm. Right, quantification of the amount of p-S19 MyoII 
(upper panel) and total MyoII (lower panel) in GFP and GFP-Asef2 cells. Error bars represent 
the s.e.m. for at least 117 cells from at least six individual experiments. *P<0.002. (B) Left, wild-
type HT1080 cells were transfected with NT shRNA or Asef2 shRNA 1. After 3 days, cells were 
immunostained for S19 phosphorylated MyoII (p-S19 MyoII) or total MyoII. Scale bar: 15 µm. 
Right, quantification of the amount of p-S19 MyoII and total MyoII in NT shRNA and Asef2 
shRNA 1 transfected cells. Error bars represent the s.e.m. for at least 58 cells from at least four 
individual experiments. *P<0.004.  
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Figure 20. Asef2 increases the levels of active MyoII in MDA-MB-231 cells to regulate 
contractility.  (D) Left, GFP and GFP-Asef2 stable MDA-MB-231 cells were plated on type I 
collagen-coated coverslips and were immunostained for phospho-S19 MyoII (p-S19 MyoII) or 
total MyoII. p-S19 MyoII and total MyoII images are shown in pseudo-color coding. Scale bar: 
15 µm. Right, quantification of the amount of p-S19 MyoII and total MyoII in GFP and GFP-
Asef2 cells is shown. Error bars represent S.E.M. for at least 30 cells from three separate 
experiments (*p = 0.0002). For panels B and D, “n.s.” denotes no statistically significant 
difference.  
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 To further demonstrate that Asef2 modulates MyoII activity in cells, we performed In-
Cell western assays. In this assay, GFP and GFP–Asef2 stably expressing HT1080 cells were 
allowed to adhere to 96-well culture plates coated with type I collagen and subsequently 
immunostained for phospho-S19 MyoII or total MyoII followed by fluorescently-conjugated 
secondary antibody. The background-subtracted integrated fluorescence intensity in each well 
was then quantified. The amount of active MyoII was ~1.7-fold higher in GFP–Asef2 cells 
compared to GFP controls, whereas the level of total MyoII was not significantly different in 
these cells (Fig. 21). Collectively, these results show that Asef2 significantly enhances the 
amount of active MyoII in cells plated on type I collagen and point to Asef2 as an important 
regulator of MyoII activity.  
 Our data also raised the question as to whether Asef2 regulates cell migration on type I 
collagen through its ability to modulate MyoII activity. To address this question, we inhibited 
MyoII with blebbistatin, which impairs the ATPase activity of MyoII (Kovacs et al., 2004; 
Straight et al., 2003), and assessed migration. Treatment of GFP control cells with blebbistatin 
led to an increase in migration speed (Fig. 22A, B), which is consistent with previous studies 
(Even-Ram et al., 2007; Liu et al., 2010; Niggli et al., 2006). At the end of the migration assay, 
we performed washout experiments to show that the effects on migration were due to 
blebbistatin. In these experiments, blebbistatin-containing medium was removed, cells were 
washed, fresh medium without blebbistatin was added, and cells were used in migration assays. 
The migration speed of GFP cells after washout was decreased compared to that observed in 
GFP cells treated with blebbistatin (Fig. 22A, B). Indeed, the migration speed of GFP cells 
following washout was similar to that seen in vehicle-treated control cells (Fig. 22A, B). 
Consistent with our previous results, the migration speed of GFP–Asef2 cells was decreased 
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when compared to GFP cells. Treatment of GFP–Asef2 cells with blebbistatin resulted in a 
significant increase in migration speed, and blebbistatin washout negated the increase in 
migration (Fig. 22A,B), indicating that MyoII activity is crucial for the effect of Asef2 on 
migration. Collectively, our data suggest that Asef2 regulates migration by modulating MyoII 
activity and function. 
 We had previously shown that Asef2 regulates cell migration on fibronectin by a 
mechanism that is dependent on Rac and the serine/threonine kinase Akt (Bristow et al., 2009). 
Here, we demonstrate that Asef2 modulates migration on type I collagen by increasing Rac and 
MyoII activity. This raises the question as to whether Akt also contributes to the regulation of 
Asef2- mediated migration on type I collagen. To address this question, we plated GFP and 
GFP–Asef2 stably expressing HT1080 cells on type I collagen and immunostained with antibody 
against Akt phosphorylated on threonine 308 (phospho-T308 Akt). T308 is one of the key 
residues that is phosphorylated when Akt is activated; therefore, phospho-T308 Akt antibody can 
be utilized to detect active Akt (Alessi et al., 1996). Interestingly, the amount of active Akt was 
similar in GFP and GFP–Asef2 cells plated on type I collagen (Fig. 23C), suggesting that the 
Asef2-Rac signaling mechanisms are different for cells plated on fibronectin and type I collagen. 
To further investigate Asef2-Rac signaling on these substrates, we plated GFP and GFP-Asef2 
stably expressing HT1080 cells on fibronectin and immunostained for active MyoII with 
phospho-S19 MyoII antibody. The amount of active MyoII was not significantly different in 
GFP and GFP-Asef2 cells plated on fibronectin (Fig. 23D). Therefore, our results suggest that 
Asef2-Rac signaling regulates migration on fibronectin and type I collagen by distinct molecular 
mechanisms. 
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Figure 21. Asef2 increases phosphorylation of MyoII at S19. (C) GFP and GFP–Asef2 cells 
were subjected to In-Cell western analysis using antibodies against S19 phosphorylated MyoII 
(p-S19 MyoII) or total MyoII. Left, quantification of the amount of p-S19 MyoII in GFP and 
GFP-Asef2 cells. Error bars represent s.e.m. from four separate experiments. *P<0.001. Right, 
quantification of the amount of total MyoII in GFP and GFP–Asef2 cells. Error bars represent 
the s.e.m. from four separate experiments. n.s. denotes no statistically significant difference.  
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Figure 22. Inhibition of MyoII with blebbistatin enhances basal migration and abolishes 
the Asef2-mediated decrease in migration on type I collagen. (A) GFP and GFP–Asef2 stably 
expressing HT1080 cells were pre-treated with 20 µM blebbistatin or vehicle (DMSO) for 1 hour 
at 37°C and then used in migration assays. After 6 hours, blebbistatin was replaced with fresh 
imaging medium (Washout), and cells were imaged for an additional 6 hours. Rose plots of the 
migration tracks for five cells for each treatment are shown. (B) Quantification of the migration 
speed for GFP and GFP–Asef2 cells with the indicated treatments. Error bars represent s.e.m. for 
at least 30 cells from three independent experiments. *P<0.0001.   
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Figure 23. Asef2 regulates migration on fibronectin and type I collagen through distinct 
molecular mechanisms. (C) GFP and GFP-Asef2 stable HT1080 cells were plated on type I 
collagen- coated glass coverslips and immunostained for Akt phosphorylated at T308 (p-T308 
Akt) or total Akt. Right, quantification of the amount of p-T308 Akt (left panel) and total Akt 
(right panel) in GFP and GFP-Asef2 cells is shown. Error bars represent S.E.M. for at least 30 
cells from at least three separate experiments. (D) Left, GFP and GFP-Asef2 stable HT1080 cells 
were plated on fibronectin- coated glass coverslips and immunostained for MyoII 
phosphorylated at S19 (p-S19 MyoII) or total MyoII. p-S19 MyoII and total MyoII images are 
shown in pseudo-color coding. Scale bar: 15 µm. Right, quantification of the amount of p-S19 
MyoII (upper panel) and total MyoII (lower panel) in GFP and GFP-Asef2 cells is shown. Error 
bars represent S.E.M. for at least 55 cells from three independent experiments. For panels C and 
D, “n.s.” denotes no statistically significant difference.  
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Activation of Rac by Asef2 regulates MyoII contractility  
 Because Asef2 increased the amount of active Rac and modulated MyoII activity, we 
hypothesized that Rac regulates MyoII contractility. To begin to test this hypothesis, we used 
two shRNA constructs to knockdown endogenous expression of Rac and then assessed MyoII 
activity by immunostaining with phospho-S19 MyoII antibody. These shRNAs have been 
previously shown to knockdown endogenous Rac expression in HT1080 cells by ~75% (Bristow 
et al., 2009). Transfection of GFP stably expressing HT1080 cells with the Rac shRNAs led to an 
~2-fold reduction in the amount of active MyoII compared with that observed in cells transfected 
with pSUPER or NT shRNA (Fig. 24A), indicating that inhibition of basal Rac expression 
significantly decreased the level of active MyoII. In GFP-Asef2 stably expressing HT1080 cells, 
the level of active MyoII was significantly increased compared with control cells, and expression 
of the Rac shRNAs dramatically reduced the amount of active MyoII in these cells (Fig. 24A). 
Indeed, the level of active MyoII in GFP-Asef2 cells transfected with the Rac shRNAs was 
similar to that observed in GFP cells transfected with these knockdown constructs (Fig. 24A), 
indicating that Rac knockdown abrogated the Asef2-mediated effect on MyoII activity. Similar 
results were obtained when GFP and GFP-Asef2 cells were treated with the Rac inhibitor 
NSC23766 (supplementary material Fig. 25A). Neither the Rac shRNAs nor NSC23766 affected 
the level of total MyoII in cells (Fig. 24A; supplementary material Fig. 25A). Taken together, 
these results suggest that Rac activity regulates the amount of active MyoII in cells, and Asef2 
regulates MyoII through Rac.  
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Figure 24. Activation of Rac by Asef2 stimulates active levels of MyoII. (A) Left, GFP and 
GFP–Asef2 stably expressing HT1080 cells were co- transfected with mCherry and either empty 
pSUPER vector, a NT shRNA or Rac shRNAs. After 3 days, cells were immunostained with 
antibodies that recognize S19 phosphorylated MyoII (p-S19 MyoII; upper panels) or total MyoII 
(lower panels). Scale bar: 15 µm. Right, quantification of the level of p-S19 MyoII (upper panel) 
and total MyoII (lower panel) in GFP and GFP–Asef2 cells. Error bars represent s.e.m. for 30 
cells from three individual experiments. *P<0.002. n.s. denotes no statistically significant 
difference.  
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Figure 25. Asef2 regulates the levels of active MyoII through Rac. (A) GFP and GFP-Asef2 
stable HT1080 cells were treated with the Rac inhibitor NSC23766 or DMSO and were 
immunostained with antibodies that recognize S19 phosphorylated MyoII (p-S19 MyoII) or total 
MyoII. Quantification of the amount of p-S19 MyoII (left panel) and total MyoII (right panel) in 
GFP and GFP-Asef2 cells is shown. Error bars represent S.E.M. for 40 cells from three 
individual experiments (*p < 0.002; **p < 0.006).  
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 Next, we examined the effect of Rac activity on Asef2- mediated contractility by using 
GFP and GFP–Asef2 cells that were treated with NSC23766 in gel contraction assays. In GFP-
Asef2 cells, the gel diameters were significantly reduced compared to those observed in GFP 
cells (Fig. 26B), demonstrating that Asef2 enhances contractility. Treatment of GFP-Asef2 cells 
with NSC23766 diminished the increased contractility (Fig. 26B), suggesting that Rac activity 
induced by Asef2 promotes the enhanced contractility observed with these cells. To further show 
that Rac modulated contractility, we knocked down Rac in GFP–Asef2 cells using the two Rac 
shRNAs. Consistent with our previous results, GFP-Asef2 cells transfected with empty pSUPER 
vector or a NT shRNA showed enhanced contractility, with their gel diameters contracted to less 
than half of their original diameters (Fig. 26C). Transfection of GFP-Asef2 cells with the Rac 
shRNAs led to significantly less gel contraction compared to that seen with cells transfected with 
pSUPER or NT shRNA (Fig. 26C). Collectively, our results show that Asef2 increases gel 
contraction through Rac, thus, highlighting an important new role for Rac in regulating 
contractility within cells.  
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Figure 26. Activation of Rac by Asef2 promotes cell contractility. (B) GFP and GFP-Asef2 
stably expressing HT1080 cells were incubated with the Rac inhibitor NSC23766 or DMSO and 
then used in type I collagen gel contraction assays. Upper, images of contracted gels from GFP 
and GFP-Asef2 cells treated with DMSO or NSC23766. Lower, quantification of gel contraction 
for GFP and GFP-Asef2 cells with the indicated treatments. Error bars represent the s.e.m. from 
three individual experiments. *P<0.0001. (C) GFP-Asef2 stably expressing HT1080 cells were 
co-transfected with mCherry and empty pSUPER vector, a NT shRNA, or Rac shRNAs and were 
used in type I collagen gel contraction assays 3 days later. Upper, images of contracted gels from 
cells transfected with the indicated constructs. Lower, quantification of gel contraction for cells 
transfected with the indicated constructs. Error bars represent s.e.m. from three individual 
experiments. *P<0.004. For panels B and C, the gel circumferences are outlined with dotted 
white lines.  
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Discussion 
 Actomyosin contractility plays a crucial role in regulating cell migration through its 
ability to modulate underlying processes (Clark et al., 2007). Rho is a well-characterized 
regulator of actomyosin contractility (Wheeler and Ridley, 2004), but the function of other 
GTPases, such as Rac, in controlling this process is currently poorly understood. Here, we 
demonstrate that activation of Rac by Asef2 increases MyoII contractility to inhibit cell 
migration. Knockdown of endogenous Rac using shRNAs or inhibition of Rac activation resulted 
in a significant decrease in MyoII activity as determined by immunostaining for phosphorylated 
S19 on MyoII RLCs. In addition, Rac knockdown or inhibition led to a decrease in cell 
contractility. In contrast, an increase in Rac activity by Asef2 induced MyoII S19 
phosphorylation and significantly enhanced cell contractility. Thus, we demonstrate a new 
function for Rac in regulating actomyosin contractility, which is important for cell migration.  
 Rac is likely to modulate actomyosin contractility through downstream effectors. One 
possibility is PAK, which has been shown to phosphorylate RLCs of MyoII on S19 (Chew et al., 
1998; Kiosses et al., 1999; Zeng et al., 2000). Moreover, expression of constitutively active Rac 
led to an increase in S19 phosphorylation of MyoII RLCs, which was mediated, at least in part, 
through PAK (Brzeska et al., 2004). However, other studies have shown that PAK 
phosphorylates and inhibits myosin light chain kinase (MLCK), which activates MyoII through 
phosphorylation of S19 (Goeckeler et al., 2000; Sanders et al., 1999; Wirth et al., 2003). In this 
case, activation of PAK would decrease MyoII contractility through inhibition of MLCK. 
Clearly, the effects of PAK on contractility are complex and probably involve the interplay 
between PAK and other regulators. Therefore, it is entirely possible that other Rac effectors are 
involved in mediating Rac- induced MyoII-dependent contractility. Identifying the specific Rac 
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effectors that modulate contractility represents an exciting avenue for future studies.  
 A known function of MyoII contractility is to promote the maturation of adhesions (Choi 
et al., 2008; Chrzanowska-Wodnicka and Burridge, 1996). Our results show that Asef2 generates 
large adhesions that turn over slowly in protrusive regions of cells. Asef2 activation of Rac 
increases actomyosin contractility, which could serve to induce the maturation of adhesions. As a 
result, the nascent adhesions that form at the leading edge do not disassemble, but instead 
continue to grow into large focal adhesions. These large, mature adhesions can impair cell 
migration given that adhesion turnover at the leading edge is essential for driving rapid migration 
(Laukaitis et al., 2001; Webb et al., 2004). 
 In this study, we show that Asef2 activation of Rac inhibits cell migration, when cells are 
plated on type I collagen, through regulation of actomyosin contractility. We previously 
demonstrated that Asef2 promotes migration on fibronectin through activation of Rac and the 
serine/threonine kinase Akt, which subsequently leads to a decrease in Rho activity (Bristow et 
al., 2009). Interestingly, in both cases, Asef2 modulates cell migration by increasing Rac 
activity; however, the effects on migration and contractility are quite different. Although the 
factors that contribute to these differences are currently unknown, it is tempting to speculate that 
scaffolding proteins are involved. Scaffolding proteins can recruit or bring together various 
binding partners, through their multiple protein–protein interaction domains, and dictate 
signaling to various downstream targets (Pawson, 2007). Through the recruitment of Asef2, Rac 
and particular downstream effectors, scaffolding proteins could provide a mechanism for 
specificity in Rac signaling. Another Rac GEF, Tiam1, has been shown to associate with 
different scaffolding proteins to selectively activate distinct downstream Rac effectors 
(Buchsbaum et al., 2002; Buchsbaum et al., 2003). Scaffolding proteins could also contribute to 
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the selectivity of the GTPases by recruiting Asef2 and Rac to the complex to enhance Asef2 
activation of Rac over other GTPases, such as Cdc42. Interestingly, our results show that Asef2 
activates Rac, but not Cdc42, when cells are plated on type I collagen. The interaction of Asef2 
and distinct scaffolding proteins could provide a mechanism by which this GEF could selectively 
activate one GTPase instead of another. 
 In summary, our study has uncovered an unconventional mechanism by which Rac 
regulates cell migration. Activation of Rac by Asef2 enhances MyoII contractility, which had 
been classically thought to be mediated by Rho. Asef2, through Rac, promotes the 
phosphorylation of S19 in the RLCs of MyoII to increase actomyosin contractility. The increased 
actomyosin contractility, in turn, might affect underlying migratory processes, such as adhesion 
dynamics, to modulate cell migration.  
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Summary 
 Cell migration is fundamental to a variety of physiological processes, including tissue 
development, homeostasis, and regeneration. Migration has been extensively studied with cells 
on 2-dimensional (2D) substrates, but much less is known about cell migration in 3D 
environments. Tissues and organs are 3D, which is the native environment of cells in vivo, 
pointing to a need to understand migration and the mechanisms that regulate it in 3D 
environments. To investigate cell migration in 3D environments, we developed microfluidic 
devices that afford a controlled, reproducible platform for generating 3D matrices. Using these 
devices, we show that the Rho family guanine nucleotide exchange factor (GEF) Asef2 inhibits 
cell migration in 3D type I collagen (collagen I) matrices. Treatment of cells with the myosin II 
(MyoII) inhibitor blebbistatin abolished the decrease in migration by Asef2. Moreover, Asef2 
enhanced MyoII activity as shown by increased phosphorylation of serine 19 (S19). Furthermore, 
Asef2 increased activation of Rac, which is a Rho family small GTPase, in 3D collagen I 
matrices. Inhibition of Rac activity by treatment with the Rac-specific inhibitor NSC23766 
abrogated the Asef2-promoted increase in S19 MyoII phosphorylation. Thus, our results indicate 
that Asef2 regulates cell migration in 3D collagen I matrices through a Rac-MyoII-dependent 
mechanism.  
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Introduction 
 Cell migration is critical to many biological processes, such as tissue morphogenesis, 
tissue homeostatsis, as well as tissue regeneration and wound repair (Vicente-Manzanares and 
Horwitz, 2011).  Much of our knowledge to date has been obtained from studying cells migrating 
on 2D substrates.  Migration on 2D substrates can be described as a four-step cycle that includes 
extension of lamellipodia at the leading edge, assembly of cell-extracellular matrix (ECM) 
adhesions, forward translocation of the cell body, and retraction of the rear of the cell 
(Lauffenburger and Horwitz, 1996; Vicente-Manzanares et al., 2005).  While some aspects of 
cell migration on 2D substrates are recapitulated in 3D environments, the specific mechanisms 
and regulation of migration can be dependent on the dimensionality of the matrix (Doyle et al., 
2013).  Indeed, recent studies with 3D cell culture models, which more closely mimic the 
microenvironment of tissues, have identified differences in cell morphology and modes of 
migration when compared with cell migration on 2D substrates (Baker and Chen, 2012; 
Cukierman et al., 2001; Petrie et al., 2012; Sahai and Marshall, 2003).  For example, cells 
migrating in 3D matrices typically adopt a more elongated morphology and extend dendritic-like 
protrusions instead of the broad lamellipodia observed with cells migrating on 2D substrates 
(Cukierman et al., 2001; Petrie et al., 2012).  Cells migrating in 3D matrices can interact with the 
ECM across their entire surfaces, unlike cells on 2D substrates which typically only attach to the 
ECM at their ventral surfaces.  These differences in cell–ECM interfaces as well as ECM 
topography may be integral to the changes in morphology and modes of cell migration seen in 
3D environments.   
 Although many of the key signaling mechanisms that modulate cell migration on 2D 
substrates are known, understanding the signaling pathways that regulate 3D migration is only in 
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its infancy.  Available data, however, point to the Rho family of small GTPases, including Rac, 
Rho, and Cdc42, as having important roles in regulating cell morphology and modes of 
migration in 3D environments (Petrie et al., 2012; Petrie and Yamada, 2012; Sahai and Marshall, 
2003; Sanz-Moreno et al., 2008).  For instance, active Rac drives cells toward an elongated, 
mesenchymal morphology that is important for fibroblast migration in 3D collagen matrices 
(Petrie et al., 2012; Sanz-Moreno et al., 2008).  In contrast, active Rho signaling induces tumor 
cells to adopt a more rounded morphology that allows for an “amoeboid” mode of migration 
through 3D matrices (Sahai and Marshall, 2003).    
  The activity of these Rho GTPases, which is central to their function in migration, is 
controlled by GEFs and GTPase-activating proteins (GAPs).  GEFs facilitate the exchange of 
GDP for GTP, which serves to activate the GTPases, whereas GAPs stimulate their intrinsic 
GTPases activity, returning the small GTPases to an inactive state.  Active Rho GTPases can 
interact with downstream effectors to propagate the signal and illicit biological responses.  
Because Rho GTPase activation is controlled by GEFs, these proteins have been increasingly 
receiving attention as important regulators of cell migration (Goicoechea et al., 2014).  Despite 
this recent interest, we still have a great deal to learn about the role of GEFs in modulating cell 
migration, especially their function in regulating cell migration in 3D environments.       
 Asef2 is a newly identified Rho family GEF that has been shown to regulate migration on 
2D substrates (Bristow et al., 2009; Jean et al., 2013; Kawasaki et al., 2007; Sagara et al., 2009).  
Our previous work demonstrated that Asef2 impairs cell migration on 2D collagen I by 
increasing activation of Rac, which subsequently enhances MyoII activity (Jean et al., 2013).  
MyoII is an actin motor protein whose major function in cells is to generate contraction by 
sliding actin filaments relative to each other.  MyoII contractility (activity) is controlled by 
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phosphorylation within its regulatory light chains (RLC) (Adelstein and Conti, 1975; Scholey et 
al., 1980).  Specifically, phosphorylation of serine 19 (S19) is crucial for activation of the MyoII 
motor domain, and phosphorylation of threonine 18 further increases MyoII activity (Adelstein 
and Conti, 1975; Ikebe, 1989).  Although MyoII activity is classically thought to be mediated by 
Rho signaling (Wheeler and Ridley, 2004), our previous data reveal that activation of Rac by 
Asef2 modulates MyoII activity, and this is an important regulatory mechanism for cell 
migration on 2D substrates (Jean et al., 2013).  However, the role of Asef2 and the contribution 
of Asef2-Rac-MyoII signaling to cell migration in 3D environments is unknown.   
 In this study, we demonstrate that Asef2 inhibits HT1080 cell migration in 3D collagen I 
matrices. Asef2 increases Rac activity, which subsequently enhances S19 MyoII 
phosphorylation.  Inhibition of MyoII activity negates the Asef2-mediated effect on migration, 
suggesting that Asef2 regulates migration in 3D collagen I matrices via a Rac-MyoII-dependent 
mechanism.   
 
Materials and Methods 
Fabrication and assembly of microfluidic devices   
 The microfluidic cell culture devices were fabricated using standard soft-lithography 
techniques with polydimethylsiloxane (PDMS) replica molding (Ellsworth Adhesives, 
Germantown, WI) as previously described (Gao et al., 2011; Majumdar et al., 2011; McDonald 
and Whitesides, 2002; Whitesides et al., 2001).  To generate the devices, two layers of PDMS 
with the desired channels and cell chambers were bonded to a microscope coverslip.  The bottom 
PDMS layer consisted of a single large cell culture chamber (5 mm long, 4.6 mm wide, and 500 
µm in height) and inlet/outlet media channels that were 500 µm wide and 500 µm in height.  
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Inlet and outlet holes for three media reservoirs and two gel reservoirs, which were 4 mm and 3.5 
mm in diameter, respectively, were punched through the PDMS to facilitate media/gel loading 
and removal.  The large cell culture chamber was connected to the inlet/outlet media channels 
through vias formed by 1 mm diameter holes that were punched through the bottom PDMS layer.  
Four separate connecting chambers (100 µm in height) in the top PDMS layer were aligned with 
the 1 mm holes in the bottom PDMS layer, allowing media to flow through the cell chamber.  
 The two-layer design with separate inlet/outlet channels for the media and gel mixture 
allows for direct access of the nutrient media to the cell culture gel without perfusion through the 
long gel-loading channels filled with polymerized gel.  This scheme facilitates a sufficient supply 
of fresh culture media to the cells in the culture chamber to maintain their long-term health.  
Note that although media could flow freely in this vertically layered channels, the collagen I gel 
mixture did not flow backwards through the small vias during loading due to the larger fluidic 
resistance of the small holes compared with the cell chamber and the loading scheme of using 
negative pressure to withdraw the gel-cell mixture through the outlet well of the gel-loading 
channel.   
 To assemble the device, a pre-polymer PDMS solution was mixed with a curing agent at 
a ratio of 10:1 and poured over the molds for the bottom layer.  After the PDMS polymerized, it 
was peeled from the mold, and holes were punched through the PDMS for the media wells.  The 
surface of the glass coverslips (No. 1, VWR Vista Vision, Suwanee, GA) as well as the bottom 
PDMS layer were treated with oxygen plasma and then bonded together.  The top PDMS, after 
oxygen plasma treatment, was subsequently aligned and bonded to the bottom PDMS layer.  
Pyrex® cloning cylinders (10 mm x 10 mm) (Fisher Scientific, Pittsburg, PA) that served as 
media reservoirs were glued to the punched holes using the liquid PDMS mixture.  The 
	   88	  
assembled microfluidic device was placed in an oven at 70°C for 1 h to cure the glue and then 
sterilized under ultra-violet (UV) light for 1 h.   
Reagents and plasmids 
 Phospho-MLC (S19) polyclonal antibody (clone 3671) and MLC2 polyclonal antibody 
(clone 3672) were purchased from Cell Signaling (Beverly, MA).  FLAG-M2 monoclonal 
antibody was obtained from Sigma-Aldrich (St. Louis, MO).  Asef2 rabbit polyclonal antibody 
was prepared as previously described (Bristow et al., 2009).   Alexa Fluor® 647 anti-rabbit was 
from Molecular Probes (Eugene, OR).  IRDye 680 anti-mouse was obtained from Rockland 
Immunochemicals (Gilbertsville, PA).  Rat tail type I collagen was purchased from BD 
Biosciences (Bedford, MA).  Bovine serum albumin (BSA), blebbistatin, and NSC23766 were 
from EMD Bioscience (La Jolla, CA).  Aqua Poly/Mount mounting solution (Cat # 18606) was 
purchased from Polysciences, Inc. (Warrington, PA).    
 GFP-tagged Asef2 cDNA was generated by cloning full-length Asef2 cDNA into 
pEGFP-C3 vector as previously described (Bristow et al., 2009).  Wild-type Rac1 and GST-
tagged PBD were kindly provided by Alan Hall (Memorial Sloan-Kettering Cancer Center, NY).  
Asef2 shRNAs were prepared by ligating 64-mer oligonucleotides into pSUPER vector as 
previously described (Wegner et al., 2008; Zhang and Macara, 2008a).  The target sequences for 
Asef2 were previously described in Bristow et al. (Bristow et al., 2009).  The non-target 
sequence, 5’-CAGTCGCGTTTGCGACTGG-3’, was used as a control (Saito et al., 2007).   
Cell culture 
 HT1080 cells stably expressing GFP or GFP-Asef2 were made using retroviral induction 
as previously described (Bristow et al., 2009).  Cells were passaged in Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine 
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serum (FBS)  (Hyclone, Logan, UT) and penicillin/streptomycin (Invitrogen) (culture media).   
Preparation and loading of 3D collagen I matrices and cells into microfluidic devices 
 Collagen I was mixed to a final concentration of 1.5 µg/ml in DMEM or PBS and 
neutralized with 1N NaOH (23 ml x the volume of collagen I solution) on ice.  Cells were 
dissociated and resuspended in culture media (100,000 cells/ml) on ice.  Prior to cell loading, 
microfluidic devices were equilibrated with culture media.  Then, 100 ml of collagen I solution 
was mixed with 100 ml of the cell suspension, loaded into the cell chamber of the microfluidic 
devices, and incubated for approximately 30 min at 37°C to allow the collagen I gel with 
embedded cells to solidify.   Subsequently, culture media was flowed through the microfluidic 
devices overnight at 37°C to permit the embedded cells sufficient time to attach and extend 
protrusions.  Cells were then used in either migration assays or for immunocytochemistry.  In 
some experiments, GFP and GFP-Asef2 cells embedded in 3D collagen I matrices were treated 
with 200 µM NSC23766 or DMSO (vehicle control) for 5 h at 37°C before performing 
immunocytochemistry. 
Microscopy and immunocytochemistry 
 Cells in 3D matrices were washed by flowing phosphate buffered saline (PBS; Life 
Technologies, Grand Island, NY) through the microfluidic devices.  Cells were then fixed with 
4% paraformaldehyde and 4% sucrose for 20 min at 37°C, washed with PBS, and treated with 
0.1M glycine in PBS for 30 min.  Cells were permeabilized with 0.5% (v/v) Triton X-100 in PBS 
for 30 min at 23°C and incubated with 2% BSA with 0.3% Triton X-100 in PBS (blocking 
solution) for 1 h at 23°C to block non-specific antibody binding.  Following blocking, cells were 
incubated overnight at 4°C with primary antibody, washed with 0.3% Triton X-100 in PBS, and 
subsequently treated with blocking solution for 1 h at 23°C.  Fluorescently-conjugated secondary 
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antibodies, which were diluted in blocking solution, were incubated with cells for 1 h at 23°C.  
After antibody incubation, cells were washed with 0.3% Triton X-100 in PBS followed by PBS 
and finally sterile ddH2O.  Three drops of Prolong Gold Antifade reagent (Invitrogen, Carlsbad, 
CA) were added to the devices before imaging.   
  Images were collected using a Quorum WaveFX spinning disk confocal system with an 
inverted Nikon Eclipse Ti microscope, which was equipped with a Hamamatsu ImageEM-CCD 
camera and a PlanApo 60X TIRF objective (NA 1.49).  For excitation of GFP, a 491 nm laser 
line was used, and GFP was imaged using a 525/50 emission filter (Semrock, Rochester, NY).  
Alexa Fluor 647 was excited with a 642 nm laser line and imaged using a 700/75 emission filter 
(Semrock, Rochester, NY).  The background-subtracted, average fluorescence intensities 
(normalized to cell areas) of phosphorylated (S19) MyoII and total MyoII amounts were 
obtained with MetaMorph software.   
Migration in 3D collagen I matrices 
 Prior to imaging, SFM4MAb™ media (Hyclone, Logan, UT) supplemented with 2-5% 
FBS was added to the microfluidic devices and flowed through the 3D collagen I matrices.  
Images were acquired every 5 min for 6 h.   At each time point, sequential z-planes images were 
collected in 5 mm increments, and the z-stack with the best focal plane was selected for each x, y 
coordinate.  Cell migration within the 3D matrices was tracked using MetaMorph software 
(Molecular Devices, Sunnyvale, CA), and the migration speed was calculated by dividing the 
total migration distance (mm) by the time.  To ensure that the selected cells were embedded in 
the 3D matrices, the z coordinates where the gels contacted the glass coverslips (bottom of the 
gels) were determined, and images were collected 50-200 mm above this point.  Live-cell 
imaging in 3D matrices was performed on a Quorum WaveFX spinning disk using a 10X ADL 
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objective (NA 0.25).  Some cells were pre-treated with 50 mM blebbistatin or DMSO (vehicle 
control) for 3 h at 37°C prior to imaging. 
Rac activity assay in 3D Collagen I matrices  
Rac activity in cells embedded in 3D collagen I matrices was assessed as previously described 
(Yamazaki et al., 2009) with some modification.  GFP and GFP-Asef2 stable cells were 
transfected with 8 µg FLAG-Rac1 cDNA (per 100 mm culture dish).  Twenty hours later, 5 X 
106 cells were mixed with DMEM and collagen I (final concentration 1.5 µg/ml).  Cell-collagen 
gel suspensions (600 µl volume) were placed in 12 well plates and incubated overnight at 37°C.   
The gels were then homogenized in 50 mM Tris, 100 mM NaCl, 2 mM MgCl2, 10% glycerol, 
1% NP-40 with a protease inhibitor cocktail, pH 7.5 (lysis buffer) by repeated passage through 1 
ml syringes with 26 gauge needles.  Active Rac in homogenized samples was determined as 
previously described for 2D assays (Jean et al., 2013; Knaus et al., 2007).  Briefly, a small 
fraction of each homogenized sample was kept to measure the amount of total Rac.  The 
remaining sample was incubated with GST-PBD, which was attached to glutathione sepharose 
beads, for 1 h at 4°C with mixing.  After washing three times with lysis buffer, bound protein 
was eluted from the sepharose beads using Laemmli sample buffer and analyzed by Western 
blot.  The amount of active Rac that was pulled down was normalized to total Rac for each 
sample. 
 
Results and Discussion 
Asef2 impairs migration in 3D collagen I matrices via MyoII 
 The microfluidic devices that we have developed offer a controlled, reproducible 
platform for generating 3D environments (Fig. 27).  Therefore, we used these devices to examine 
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the migration of HT1080 cells stably expressing GFP or GFP-Asef2 (less than 3-fold over 
endogenous) (Bristow et al., 2009; Jean et al., 2013) (Fig. 28A) in 3D collagen I matrices.  When 
GFP and GFP-Asef2 cells were mixed with a collagen I solution and loaded into the cell 
chambers of the microfluidic devices, the cells embedded in 3D matrices adopted an elongated 
morphology that is characteristic of cells in 3D environments (Cukierman et al., 2001; 
Cukierman et al., 2002) (Fig. 28B).  The migration speeds of GFP-Asef2 cells embedded in 3D 
collagen I matrices was decreased significantly compared to GFP (control) cells (Fig. 28B).  
Next, we used two Asef2 short hairpin RNAs (shRNAs) to further demonstrate that Asef2 
regulates migration in 3D collagen I matrices.  We had previously shown that these Asef2 
shRNAs decrease endogenous expression of Asef2 by approximately 65% in HT1080 cells 
(Bristow et al., 2009; Jean et al., 2013).  Transfection of Asef2 shRNA 1 or Asef2 shRNA 2 into 
HT1080 cells caused a significant increase in the migration speeds of these cells in 3D collagen I 
matrices compared to that observed with a non-targeting shRNA (NT shRNA) (Fig. 28C), 
indicating that knockdown of endogenous Asef2 promotes migration in 3D collagen I matrices.   
These results collectively show that Asef2 inhibits migration in 3D collagen I matrices, which is 
consistent with our previous observation on 2D collagen I substrates (Jean et al., 2013).   
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Figure 27. Schematics depicting the loading of 3D matrices with cells into microfluidic 
devices. (A) Assembled microfluidic devices were sterilized with UV light before loading cells. 
(B) After sterilization, a solution containing a mixture of collagen I (gold) and embedded cells 
(blue) was loaded into the cell chamber of microfluidic devices and incubated for 30 min to 
allow the gel to solidify. (C) Culture media was flowed through the microfluidic devices 
overnight to allow embedded cells sufficient time to attach and extend protrusions in the 3D 
matrices. Cells were used the following day in migration assays or for immunocytochemistry. 
(D) A cross section through the cell chamber shows cells (blue) embedded in a 3D collagen I 
matrix (gold) and media flow through the cell chamber.  
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Figure 28. Asef2 hinders migration in 3D collagen I matrices. (A) Left, GFP- Asef2 cells 
were immunoblotted for Asef2. The ~100 kDa band represents GFP-Asef2, whereas the ~75 kDa 
band denotes endogenous Asef2. Right, quantification of the amount of Asef2 in GFP-Asef2 
cells. Error bars represent SEM from 3 separate experiments (*p =0.04). (B) GFP and GFP-
Asef2 cells in 3D collagen I matrices in microfluidic devices were imaged with time-lapse 
microscopy. Left, time-lapse images show GFP and GFP-Asef2 cells migrating within the 3D 
matrix (arrows). Right, the migration of individual cells was tracked, and the migration speed 
was calculated. The average migration speeds for GFP and GFP-Asef2 cells is shown. Error bars 
represent SEM for 50 cells from 3 independent experiments (*P < 0.0001). 
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Figure 28 Cont’d. Asef2 hinders migration in 3D collagen I matrices. (C) Left, wild-type 
HT1080 cells were transfected with a non-targeting shRNA (NT shRNA) or Asef2 shRNAs. 
Three days later, these cells were used in migration assays. Phase contrast images are shown 
where the blue line traces the migration path of an individual cell. Right, quantification of the 
migration speeds for cells transfected NT shRNA or Asef2 shRNAs. Error bars represent SEM 
for 26– 34 cells from 3 independent experiments (*p < 0.0001).  
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 We have previously shown that Asef2 hinders migration on 2D collagen I through a 
mechanism that is dependent on MyoII (Jean et al., 2013).  To determine if Asef2 similarly 
regulates migration in 3D collagen I matrices, we treated GFP and GFP-Asef2 cells with 
blebbistatin, an inhibitor of MyoII ATPase (Kovacs et al., 2004; Straight et al., 2003).  When 
GFP cells were incubated with blebbistatin, an increase in migration speed was observed (Fig. 
29D).  This augmentation of migration by blebbistatin treatment has been previously reported by 
us as well as by other groups (Even-Ram et al., 2007; Jean et al., 2013; Liu et al., 2010; Niggli et 
al., 2006).  Importantly, the migration speed of GFP-Asef2 cells was significantly decreased 
compared with that observed with GFP cells, and blebbistatin treatment abolished this Asef2 
effect on migration (Fig. 29D).  This result suggests that Asef2 regulates migration in 3D 
collagen I matrices through MyoII.   
Asef2 increases Rac activity in 3D collagen I matrices  
 In our previous study, we showed that Asef2 enhanced Rac activity when cells were 
plated on 2D collagen I; the augmented active Rac, in turn, increased phosphorylation of MyoII 
on S19 (Jean et al., 2013).  To determine whether Asef2 also increased the amount of Rac in 
cells in 3D collagen I matrices, we utilized a Rac activity assay.  In this assay, the p21-binding 
domain (PBD), from p21-activated kinase (PAK), is tagged with glutathione-S-transferase (GST) 
and used to pull down the active form of Rac.  PAK is an effector that only binds to the active 
form of Rac (Knaus et al., 1995; Manser et al., 1994; Martin et al., 1995).  When GFP and GFP-
Asef2 cells were embedded in collagen I matrices, and Rac activity was assessed, an almost 3-
fold increase in the amount of active Rac was seen in GFP-Asef2 cells compared to that observed 
in GFP cells (Fig. 30).  This result indicates that Asef2 induces activation of Rac in 3D collagen I 
matrices.   
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Figure 29. Inhibition of MyoII abolished the Asef2-mediated decrease in migration in 3D 
collagen I matrices. (D) GFP and GFP-Asef2 cells were treated with 50 µM blebbistatin or 
DMSO (vehicle control) for 3 h at 37°C prior to being used in 3D migration assays.  The average 
migration speed for GFP and GFP-Asef2 cells, subjected to the indicated treatments, was 
quantified.  Error bars represent S.E.M. for 50 cells from three independent experiments (*p = 
0.003; **p < 0.0001).   
	  
 
Figure 30. Asef2 augments Rac activity in 3D collagen I matrices.  Left, GFP and GFP-Asef2 
cells were transfected with FLAG-Rac1 cDNA.  Twenty-four hours later, these cells were 
embedded in 3D collagen I matrices and incubated overnight.  Then, the matrices with embedded 
cells were homogenized, and active Rac was pulled down from homogenized samples.  Total 
Rac is shown as a control.  Right, quantification of active Rac levels in homogenized samples of 
GFP and GFP-Asef2 cells in 3D matrices from at least three separate experiments is shown.  
Error bars represent S.E.M. (*p < 0.005). 
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Asef2 promotes S19 phosphorylation of MyoII through Rac  
 Because our results demonstrate that MyoII activity is important for the Asef2-mediated 
modulation of cell migration in 3D collagen I matrices (Fig. 29D), we next examined the effect 
of Asef2 on MyoII S19 phosphorylation.  Phosphorylation of S19 within the RLC of MyoII is 
critical for its activation; therefore, phosphorylation of this amino acid can be utilized to gauge 
MyoII activity (Ikebe, 1989; Matsumura et al., 1998).  GFP and GFP-Asef2 cells were embedded 
in 3D collagen I matrices and subsequently immunostained with an antibody that recognizes 
MyoII phosphorylated at S19.  The amount of S19 phosphorylated MyoII (p-S19 MyoII) was 
significantly increased in GFP-Asef2 cells compared to GFP cells (Fig. 31A), whereas the 
amount of total MyoII was similar in these cells (Fig. 31B).  Moreover, we observed a 1.4 ± 0.2-
fold (n = 2 separate experiments) increase in the amount of p-S19 MyoII in GFP-Asef2 cells 
compared to GFP cells, as determined by In-cell Western analysis, which was performed as 
previously described (Jean et al., 2013).  In contrast, the amount of total MyoII was not 
significantly different in GFP and GFP-Asef2 cells.   These results demonstrate that Asef2 
enhances the amount of active MyoII in cells in 3D collagen I matrices.   
 Because we have previously shown that Asef2 increases the level of active MyoII on 2D 
collagen I via Rac, we investigated the contribution of Rac to the Asef2-promoted increase in 
MyoII activity.  GFP and GFP-Asef2 cells, embedded in 3D collagen I matrices, were treated 
with the Rac inhibitor NSC23766, and S19 MyoII phosphorylation was assessed.  Treatment of 
GFP cells with NSC23766 resulted in a decrease in S19 phosphorylated MyoII (p-S19 MyoII) 
(Fig. 31A), suggesting that inhibition of basal Rac activity diminished the amount of active 
MyoII.  Interestingly, treatment of GFP-Asef2 cells with NSC23766 abolished the Asef2-
promoted increase in active MyoII (Fig. 31A).  The level of total MyoII was similar in GFP and 
GFP-Asef2 cells and was not affected by NSC23766 treatment (Fig. 31B).  These results suggest 
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that Asef2 enhances MyoII activity through a Rac-dependent mechanism in cells in 3D collagen 
I matrices.   
 Our results indicate that Asef2 activates Rac and inhibits the migration of HT1080 cells 
in 3D collagen I matrices.  Others Rac GEFs, including DOCK3 and P-Rex, have also been 
shown to regulate the migration of tumor cells in 3D environments (Campbell et al., 2013; Sanz-
Moreno et al., 2008), pointing to the importance of GEFs in modulating 3D migration.  The 
DOCK3-stimulated activation of Rac promoted an elongated, mesenchymal-like morphology of 
melanoma cells and suppressed “amoeboid” migration (Sanz-Moreno et al., 2008).   We 
observed a similar elongated morphology with Asef2-expressing HT1080 cells in 3D collagen I 
matrices.   The effect that the Asef2-mediated activation of Rac has on amoeboid movement is 
currently unknown, but it will most likely depend on the effectors of Asef2-Rac signaling.  In 
this context, Asef2 activation of Rac could recruit and target different effectors to the signaling 
complex to regulate cell morphology and migration in 3D matrices.  Identification of the Asef2-
Rac effectors that modulate 3D migration represents an exciting avenue for future study.  
 In our study, Asef2-Rac signaling increases MyoII activity, which is critical for the 
impaired migration that we observe in 3D collagen I matrices.  Indeed, our data demonstrate that 
treatment with the MyoII inhibitor blebbistatin abolished this Asef2-mediated effect on 
migration and resulted in an increase in migration speed.  Others have reported that blebbistatin 
treatment decreases migration in 3D environments (Petrie et al., 2012; Poincloux et al., 2011).    
The migration speed of human foreskin fibroblasts in cell-derived 3D matrices and human breast 
adenocarcinoma cells in 3D Matrigel were reduced following blebbistatin treatment (Petrie et al., 
2012; Poincloux et al., 2011).  Our studies were performed with HT1080 cells migrating in 3D 
collagen I matrices, whereas the previous experiments were done with other cell types migrating  
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Figure 31. Asef2 promotes S19 phosphorylation of MyoII through Rac.  (A) Left, GFP and 
GFP-Asef2 cells embedded in 3D collagen I matrices were incubated with 200 µM NSC23766 or 
DMSO for 5 h at 37°C and were subsequently immunostained for S19 phosphorylated MyoII (p-
S19 MyoII).  Scale bar = 15 µm.   Right, quantification of p-S19 MyoII levels in these cells is 
shown.  Error bars represent S.E.M. for at least 30 cells from at least three individual 
experiments (*p < 0.005; **p = 0.0001).  (B) Left, GFP and GFP-Asef2 cells embedded in 3D 
collagen I matrices were treated with NSC23766 or DMSO and immunostained for total myosin.  
Scale bar = 15 µm.  Right, quantification of total MyoII levels in these cells is shown.  Error bars 
represent S.E.M. for at least 39 cells from at least four separate experiments.  “n.s.” denotes no 
statistically significance difference. 
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in 3D cell-derived matrices or 3D Matrigel.  Therefore, the differences in matrices as well as cell 
types could contribute to the differential effect observed on migration with blebbistatin 
treatment.  Future studies will be needed to determine the reasons for this discrepancy.   
Conclusions 
 Our data suggest that Asef2 regulates cell migration in 3D collagen I matrices through 
Rac and MyoII.  Asef2 increased activation of Rac in 3D collagen I matrices, which, in turn, 
enhanced MyoII activity.  MyoII activity was critical for the Asef2 impaired migration in 3D 
collagen I matrices.  Activation of Rac has not been previously demonstrated to induce MyoII 
activity in 3D matrices; thus, it will be interesting to examine the effect of Rac activation by 
other GEFs on MyoII.   These results are consistent with our previous observations on 2D 
collagen I (Jean et al., 2013).  Therefore, these data point to a common mechanism by which 
Asef2 modulates migration on 2D collagen I substrates and in 3D matrices.  
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CHAPTER IV 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 The members of the Rho GTPase family are well demonstrated to be important regulators 
of cell migration. Cell migration is a highly coordinated and spatiotemporally regulated process 
that has been implicated in diseases such as cancer and atherosclerosis. Although it is well 
understood that GTPases regulate many aspects of intracellular actin dynamics through their 
activation by GEFs, very little is known about the specific role these GEFs play in regulating 
cellular migration.  Here, for the first time, we reveal a new role for the GTPase Rac, through 
Asef2-mediated activation, in modulating actomyosin contractility, and thereby cell migration 
and adhesion dynamics. 
 In this study, we show that activation of Rac by Asef2 inhibits cell migration on type I 
collagen (Col-I), a protein that forms the majority of the connective tissues surrounding tumors 
(Jean et al., 2013). In live-cell imaging, we observed that the migration speed of fibrosarcoma 
cells (HT1080) expressing Asef2 is significantly decreased when compared with controls. 
Additionally, stable expression of GFP-Asef2 in MDA-MB-231 breast cancer cells led to a 
significant reduction in migration speed as compared to that observed with GFP stable cells (Jean 
et al., 2013), indicating that the phenotype was not cell type specific. The specificity of Asef2’s 
role in this decreased migration effect was further confirmed with shRNA-mediated knockdown 
of endogenous Asef2. Asf2 knockdown resulted in a significant increase in migration speed 
compared to that observed with empty pSUPER vector or a non-targeting (NT) shRNA. We also 
determined the effect of Asef2 on the activity of the Rho family GTPases Rac, Cdc42, and Rho, 
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using an active GTPase pulldown assay. Interestingly, while Asef2 expression did not 
significantly affect the levels of active Cdc42 or Rho, it did increase the amount of active Rac. 
To investigate local Rac activation, we used the Raichu-Rac fluorescence resonance energy 
transfer (FRET) probe to further demonstrate that Asef2 increases Rac activity. And, as 
expected, Asef2 expression did enhance levels of active Rac. Furthermore, our data indicated 
that the GEF activity of Asef2 is critical for its function in impairing migration on Col-I.  
 Taken together, the above results suggest that Asef2 promotes the activation of Rac, and 
not Cdc42 and Rho, when cells are plated on Col-I.  Additionally, they show that the Asef2-
mediated activation of Rac results in a reduction of migration speed. It would be interesting to 
examine whether the Asef2-mediated effects on Col-I represent a general mechanism for other 
Rho family GEFs, especially Rac-specific GEFs.  First, we could increase Rac activity in cells by 
expressing the Rac-specific GEF, Tiam1 (Habets et al., 1994; Habets et al., 1995). We can then 
assess its effect on cell migration on Col-I.  If this pathway is specific to Rac, then Tiam1 will 
not similarly affect cell migration.  However, it is possible that Tiam1 and, potentially, other 
GEFs are activators of Rac in this pathway which would result in a decrease in cell migration.  
 As previously mentioned, GTPases are spatially and temporally regulated.   Studies have 
shown active Rac and Cdc42 to be localized to the leading edge of the migrating cell, while 
active Rho is present at both the front and the rear of the cell (Machacek et al., 2009; Pertz and 
Hahn, 2004; Pertz et al., 2006). However, GTPases can also regulate each other via an extensive 
crosstalk to coordinate their own activity to facilitate cell migration (Guilluy et al., 2011). This 
crosstalk frequently occurs in the form of positive or negative regulation of one GTPase by 
another. For instance, there are several examples of Rac acting upstream of Rho to stimulate its 
activation and promote the necessary contractile forces for effective migration (Burridge and 
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Wennerberg, 2004). Indeed, the protrusive activity of Rac is considered to be a necessary 
opposing force to the stabilization of stress fiber and contractile forces generated in a Rho-
dependent manner. However, other studies indicate that Rac can inactivate Rho, or vice versa 
(Burridge and Wennerberg, 2004; Sander et al., 1999). Therefore, it is clear that the multiple 
signaling pathways that result from GTPase crosstalk not only act in compliment to one another, 
but also are important in regulating migration.  
Our lab previously reported Asef2 to promote cell migration on fibronectin through Rac 
and the serine/threonine kinase Akt, which subsequently leads to a decrease in Rho activity 
(Bristow et al., 2009). Interestingly, in our current studies investigating the role of Asef2 on Col-
I,  Asef2 did not change the amount of active Rho. It would therefore be of keen interest to 
examine the differential effect of Rho inhibition on Rac activation in Asef2-mediated migration.  
One experiment would be to use FRET biosensors to determine the effect of both Asef2 
expression and Rac activation on localized Rho activity when cells are plated on Col-I versus 
fibronectin. 
 Our data also indicates a novel role for Rac in regulating Myosin II (MyoII) motor 
proteins, which bind actin filaments to provide the contractile force needed for translocation. 
Rho is a well-characterized modulator of actomyosin contractility, but the function of other 
GTPases, such as Rac, in regulating contractility is currently not well understood. Here we show 
that activation of Rac by Asef2 increases MyoII contractility to impair cell migration. Cell 
contractility was assessed using a gel contraction assay, and the diameter of Col-I gels with 
Asef2-expressing cells were reduced as compared to controls. Levels of active MyoII were also 
significantly increased by Asef2 expression, as determined by S19 phosphorylation, while 
knockdown of endogenous Asef2 led to a decrease in active MyoII. In addition, knockdown of 
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endogenous Rac using shRNAs or treatment of cells with a Rac-specific inhibitor resulted in a 
significant decrease in the amount of active MyoII, and negated the Asef2-promoted increase in 
contractility. These results, showing that Rac increases contractility, point to a new role for Rac 
regulating actomyosin contractility, which is important for cell migration. Furthermore, 
treatment of cells with blebbistatin, which inhibits MyoII activity, abolishes the Asef2-mediated 
effect on migration speed. Collectively, these results demonstrate that the Asef2-mediated 
migration on Col-I is facilitated through Rac and MyoII- dependent cell contractility, which has 
been classically thought to be mediated by Rho.  It would be interesting to determine whether 
Asef2-mediated migration is mediated only though Rac, specifically looking at the effect of Rho 
inhibition on levels of active MyoII when cells are plated on Col-I. 
 Rac most likely modulates actomyosin contractility through downstream effectors (Fig 
34). Since p21-activated kinase (PAK) is an effector of Rac and directly phosphorylates MyoII 
on S19 (Chew et al., 1998; Ramos et al., 1997), PAK may serve as the link between Rac and 
MyoII. PAK regulates MyoII activity either through direct phosphorylation of the MyoII 
regulatory light chain (RLC), or indirectly through regulation of the myosin light chain kinase 
(MLCK) (Chong et al., 2001). Moreover, expression of constitutively active Rac increases S19 
phosphorylation of MyoII RLCs, which was mediated, at least in part, through PAK (Brzeska et 
al., 2004). Preliminary results show that expression of a dominant negative PAK abolishes the 
Asef2-promoted increase in the level of p-S19 MyoII, and that constitutive activation of PAK 
mimics the Asef2-mediated decrease in migration speed seen on Col-I (Fig. 32 and 33). These 
results suggest that PAK links Rac to MyoII in this signaling pathway. However, follow up 
experiments such as knockdown of endogenous PAK in Asef2-expressing  
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Figure 32. PAK negates the Asef2-promoted increase in MyoII activity. Cells expressing 
Asef2 were transfected with empty vector or a dominant negative PAK construct and 
immunostained for p-S19-MyoII. Quantification of average fluorescence intensity as a percent of 
the GFP is shown. Error bars represent the standard error mean for at least 28 cells from 2 
experiments (*p<0.0001; ANOVA-Tukey-Kramer comparison). 	  
	  
Figure 33. PAK regulates Asef2-mediated decrease in migration. Cells expressing Asef2 
were transfected with empty vector or a shRNAs constructs against PAK. Cells were then plated 
on Col-I and then imaged using time lapse microscopy. Individual cell migrations were tracked 
and their average speeds are shown. Error bars represent standard error means for at least 38 
cells over 3 experiments. (*p<0.0001; ANOVA-Tukey-Kramer comparison). 
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Figure 34. Model of Asef2 regulation of Rac and Myosin II 
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cells to examine the effect on MyoII activity, contractility, and migration would confirm the role 
of PAK in Asef2-mediated migration.  Still, we could assess whether PAK acts a mediator for 
Rac-dependent activation of MyoII, and look at the effect of endogenous knockdown of Rac on 
PAK activity using an antibody that recognizes phosphorylated threonine 423, a key 
autophosphorylation site for PAK activation (Sells et al., 2000). 
 Because the growth and stability of cell-matrix adhesions have been linked to actomyosin 
contractility (Choi et al., 2008; Chrzanowska-Wodnicka and Burridge, 1996), we also examined 
the effect of Asef2 on adhesions using total internal reflection fluorescence (TIRF) microscopy. 
Interestingly, Asef2 expression increases active levels of β1 integrin proteins in adhesions, and 
induces large and mature adhesions that assemble and disassemble (turnover) more slowly 
compared with controls. However, the Asef2-promoted increase in active β1 integrin in 
adhesions was diminished by treatment with a Rac inhibitor.  Taken together, this data further 
demonstrated a new role for Rac activation, promoted by Asef2, in modulating actomyosin 
contractility, which is important for regulating cell migration and adhesion dynamics.  According 
to our results, Asef2 activation of Rac increases actomyosin contractility, which could serve to 
induce the maturation of adhesions.  Nascent adhesions that form at the leading edge of Asef2-
expressing cells grow into large focal adhesions instead of undergoing disassembly. In turn, 
these large mature adhesions serve to inhibit cell migration given that adhesion turnover at the 
leading edge is essential for driving rapid migration (Laukaitis et al., 2001; Webb et al., 2004). 
 We could further show that the Rac-mediated increase in active MyoII is important for 
the regulation of adhesion dynamics by Asef2 by investigating the effect of MyoII inhibition on 
adhesion size and adhesion turnover using the MyoII inhibitors and mutants.  Since MyoII 
promotes adhesion maturation by contracting F-actin (Choi et al., 2008; Vicente-Manzanares et 
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al., 2007), we anticipate that MyoII inhibition will result in smaller, “immature” adhesions in 
Asef2-expressing cells.  Additionally, inhibition of MyoII induce faster adhesion assembly and 
disassembly rates in Asef2-expressing cells, allowing these cells to move faster.  Another 
experiment would be to use a Rac inhibitor and Rac shRNAs and examine the effect of decreased 
Rac activity and expression on the Asef2-mediated regulation of adhesion size and turnover. We 
expect that knockdown of Rac would lead to similar results as those obtained with MyoII 
inhibition on adhesion size and adhesion turnover. Moreover, future studies can also be carried 
out to determine whether the effects of Rac and MyoII on adhesion turnover are mediated 
through PAK using a similar approach. 
 Because three-dimensional (3D) matrices more closely mimic the physiologic 
environment of cells (Cukierman et al., 2002), it is important to test observations obtained from 
cultured cells in a more in vivo-like environment. Thus, we investigated the role of Asef2 in 
regulating migration and MyoII activity in 3D in vivo-like environments. We used microfluidic 
devices that afford a controlled reproducible platform for generating 3D Col-I matrices (Jean et 
al., 2014). Using these devices, we have shown that Asef2 inhibits cell migration in 3D Col-I 
matrices, and that treatment of these cells with blebbistatin abolishes the Asef2-mediated 
decrease in migration. Moreover, Asef2 enhances MyoII activity and treatment with a Rac 
inhibitor abolishes the Asef2-promoted increase in active MyoII. Collectively, these results 
indicate that Asef2-mediated Rac activation is critical for modulating MyoII activity and cancer 
cell migration in both 2D and 3D environments. 
 The data from this dissertation puts forth new findings in the field of cell migration and 
adhesion dynamics, in that Rac activation has not previously been linked to a reduction in 
migration (Bristow et al., 2009), and Rho has been classically shown to regulate MyoII 
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contractility (Chrzanowska-Wodnicka and Burridge, 1996; Wheeler and Ridley, 2004). 
Interestingly, it seems that though Asef2 modulates cell migration by increasing Rac activity, the 
effects on migration and contractility are quite different depending on the given ECM (i.e. Col-I 
vs fibronectin) (Bristow et al., 2009; Jean et al., 2013). These differential effects on migration 
may be attributed to different combinations of scaffolding proteins downstream of ECM 
engagement. Scaffolding proteins can recruit or bring together various binding partners through 
their multiple protein-protein interaction domains, and dictate signaling to various downstream 
targets (Pawson, 2007).  And as such, the recruitment of Asef2, Rac and other downstream 
effectors upon ECM engagement may assemble different scaffolding proteins and provide a 
mechanism for specificity in Rac signaling (Fig. 34). This hypothesis is further confirmed with 
studies on another Rac GEF, Tiam1, which has been shown to associate with different 
scaffolding proteins to selectively activate distinct downstream Rac effectors (Buchsbaum et al., 
2002; Buchsbaum et al., 2003). 
 In addition, scaffolding proteins could also promote the selectivity of GTPases by 
amplifying the recruitment of Asef2 and Rac to the signaling complex, and thus enhance Asef2 
activation of Rac over other GTPases, such as Cdc42. Interestingly, although Asef2 is a Rac and 
Cdc42 GEF, our results show that Asef2 preferentially activates Rac on Col-I. The interaction of 
Asef2 and distinct scaffolding proteins seems to provide a mechanism by which this GEF is 
selectively activating one GTPase over another. Thus, investigating the upstream mechanisms 
that regulate Asef2 activation would shed light on the sequence of events in Asef2-mediated 
signaling.  The overabundance of GEFs compared to GTPases adds an additional regulatory 
component to GTPase activity as most GEFs contain multiple protein-protein interaction 
domains that are hypothesized to target the GTPases to specific cellular regions, where they can 
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be activated by distinct upstream signals (Rossman et al. 2005).  It would be interesting to 
determine the effect of upstream signaling of various growth factors, such as epidermal growth 
factor (EGF) on the formation of the different protein complexes on Col-I and fibronectin, and 
on Asef2’s localization within migrating cells. Another approach would be to identify Asef2’s 
binding partners on Col-I and fibronectin using high-resolution mass spectrometry.  
 Asef2 is aberrantly expressed in colorectal tumors, and its expression has been shown to 
be necessary for intestinal adenoma metastasis and progression (Kawasaki et al., 2009). This 
aberrant regulation of Asef2 in colorectal tumor cells is believed to result from its interaction 
with the mutated form of the tumor suppressor adenomatous polyposis coli (APC) typically 
found in colorectal tumor cells (Kawasaki et al., 2013; Kawasaki et al., 2009). Genetic deletion 
of Asef2 in mice led to a reduction in adenoma number and size in an APCMin/+ background 
(Kawasaki et al., 2009), which is a common model of colorectal cancer (Su et al., 1992). 
Furthermore, deletion of Asef2 reduced the number of angiogenic blood vessels, indicating that 
Asef2 is required for tumor angiogenesis (Kawasaki et al., 2009). These studies show that Asef2 
contribute to adenoma formation, as well as to tumor progression in mice, via histology and 
immunohistochemistry. In contrast, because our result on Col-I suggests that Asef2 is reducing 
migration, it is possible that APC is not the activator in Asef2-mediated migration on Col-I. The 
metastasis phenotype seen on the APC background mice might be due to the fact that upstream 
activators of Asef2 specify the downstream signaling of Asef2 on different ECM. Additionally, 
our lab has observed Asef2 differentially inhibiting migration on Col-I and increasing migration 
on fibronectin by two different mechanisms. This suggest a strong role for the tumor 
microenvironment in dictating cancer cell metastasis. Further investigation of metastatic cancer 
types, and surrounding tissue may offer some insight into the localized regulation of Asef2. 
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Moreover, since aberrant cell migration is implicated in tumor cell metastasis, it would be 
interesting to address the potential role Asef2 in the regulation of metastasis in vivo using a 
viable system. 
 
Asef2: A promising target for cancer therapeutics  
 Our data point to an important role for Asef2 in regulating cancer cell migration and its 
underlying processes. By investigating the function of Asef2 in cell migration, we should gain 
significant insight into the molecular mechanisms that regulate this process, which could lead to 
new therapeutic treatments for various diseases. We are optimistic that Asef2, or other effectors 
which regulate its activity, could be a direct molecular target for controlling cancer metastasis.  
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